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ABSTRACT 
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ABSTRACT 
High blood pressure, also called hypertension is one of the most 
common worldwide diseases afflicting humans and is a major risk factor for 
stroke, myocardial infarction, vascular disease, and chronic kidney disease. 
If blood pressure is controlled and oscillations in the hemodynamic variables 
are reduced, patients experience fewer complications after surgery. In 
clinical practice, this is usually achieved using manual drug delivery. Given 
that different patients have different sensitivity and reaction time to drugs, 
determining manually the right drug infusion rates may be difficult. This is a 
problem where automatic drug delivery can provide a solution, especially if it 
is designed to adapt to variations in the patient’s conditions. 
This research work presents an investigation into the development of 
abnormal blood pressure (hypertension) controllers for postoperative 
patients. Control of the drugs infusion rates is used to simultaneously 
regulate the hemodynamic variables such as the Mean Arterial Pressure 
(MAP) and the Cardiac Output (CO) at the desired level. The implementation 
of optimal control system is very essential to improve the quality of patient 
care and also to reduce the workload of healthcare staff and costs. Many 
researchers have conducted studies earlier on modelling and/or control of 
abnormal blood pressure for postoperative patients. However, there are still 
many concerns about smooth transition of blood pressure without any side 
effect.  
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The blood pressure is classified in two categories: high blood pressure 
(Hypertension) and low blood pressure (Hypotension). The hypertension 
often occurred after cardiac surgery, and the hypotension occurred during 
cardiac surgery. To achieve the optimal control solution for these abnormal 
blood pressures, many methods are proposed, one of the common methods 
is infusing the drug related to blood pressure to maintain it at the desired 
level. There are several kinds of vasodilating drugs such as Sodium 
Nitroprusside (SNP), Dopamine (DPM), Nitro-glycerine (NTG), and so on, 
which can be used to treat postoperative patients, also used for hypertensive 
emergencies to keep the blood pressure at safety level. 
A comparative performance of two types of algorithms has been 
presented in chapter four. These include the Internal Model Control (IMC), 
and Proportional-Integral-Derivative (PID) controller. The resulting controllers 
are implemented, tested and verified for three sensitivity patient response. 
SNP is used for all three patients’ situation in order to reduce the pressure 
smoothly and maintain it at the desire level. A Genetic Algorithms (GAs) 
optimization technique has been implemented to optimise the controllers’ 
parameters. A set of experiments are presented to demonstrate the merits 
and capabilities of the control algorithms. The simulation results in chapter 
four have demonstrated that the performance criteria are satisfied with the 
IMC, and PID controllers. On the other hand, the settling time for the PID 
control of all three patients’ response is shorter than the settling time with 
IMC controller. 
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 Using multiple interacting drugs to control both the MAP and CO of 
patients with different sensitivity to drugs is a challenging task. A 
Multivariable Model Reference Adaptive Control (MMRAC) algorithm is 
developed using a two-input, two-output patient model. Because of the 
difference in patient’s sensitivity to the drug, and in order to cover the wide 
ranges of patients,   Model Reference Adaptive Control (MRAC) has been 
implemented to obtain the optimal infusion rates of DPM and SNP. This is 
developed in chapters five and six.   
Computer simulations were carried out to investigate the performance 
of this controller. The results show that the proposed adaptive scheme is 
robust with respect to disturbances and variations in model parameters, the 
simulation results have demonstrated that this algorithm cannot cover the 
wide range of patient’s sensitivity to drugs, due to that shortcoming, a PID 
controller using a Neural Network that tunes the controller parameters was 
designed and implemented. The parameters of the PID controller were 
optimised offline using Matlab genetic algorithm. The proposed Neuro-PID 
controller has been tested and validated to demonstrate its merits and 
capabilities compared to the existing approaches to cover wide range of 
patients. 
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Chapter 1.  
INTRODUCTION 
1.1 Background 
Postoperative hypertension is a well-known complication of cardiac 
surgery patients and in 56-100% of cases of surgical coarctation repair. In 
fact, many studies have tried to find out the reasons of the increase in the 
blood pressure of the postoperative patients reported by Fox et al. in 1980 
[1], and Rocchini et al. in 1976 [2]. Sodium Nitroprusside (SNP) is a powerful 
anti-hypertension drug. It quickly lowers the blood pressure in most 
postoperative patients and must be given intravenously with careful 
manipulation of the infusion rate to toxic side effects, reported by Tuzel in 
1974 [3], Engeser et al. in 1982 and Ma in 2000 [4, 5]. The infusion of SNP 
and its effect on biological system poses a real problem in postoperative 
patients that has been reported by Treesatayapun in 2005 [6], Slate et al. in 
1982 [7], Hahn et al. in 2002 [8] and Isaka et al. in 1993 [9]. The use of an 
automatic drug infusion control system in order to regulate the patients’ blood 
pressure would reduce this complication in postoperative patients. In 1982, 
Slate and Sheppard developed a model for patients’ response that showed 
there are large variations in the model parameters for different patients and 
their responses to the drug. This model has been used by many researchers 
to design several controllers such as the ones presented by Hahn et al. in 
2002 [8] and Isaka et al. in 1993 [9]. 
 
CHAPTER 1. - INTRODUCTION  
 
2 
 
 
In most post open heart surgery, patient suffers from hypertension 
which is caused by a severe vasoconstriction. An immediate use of 
vasodilator drugs is strongly recommended in order to reduce the risk of 
complications. Hemodynamic variables such as Mean Arterial Pressure 
(MAP) and Cardiac Output (CO) are commonly controlled using more than 
one drug. Several studies have investigated the automation of multiple drug-
deliveries. Yu et al. in 1990 have developed a computer model to simulate 
the hemodynamic responses to Dopamine (DPM) and Sodium Nitroprusside 
(SNP) in a failing heart. They simulated the circulatory system with a 
nonlinear electrical analog model with baroreflex feedback [10]. Achuthan et 
al. in 1999 have used the computer model which was developed by Yu et al. 
in 1990 to test an indirect adaptive algorithm based on parameter 
identification and linear quadratic regulation [11]. Voss et al. in 1987 
implemented an adaptive algorithm to control MAP and CO in anesthetized 
dogs with infusion of SNP and DPM [12]. Yu et al. in 1992 proposed an 
algorithm that utilized six model predictive controllers to regulate MAP and 
CO by administering positive inotropic and vasoactive drugs DPM and SNP 
respectively. They carried out tests on laboratory animals that were altered to 
exhibit symptoms of congestive heart failure [13]. Experiments on animal 
using multi-drug administration were also done by Koivo et al. in 1978 [14], 
Koivo in 1980 and 1981 [15, 16], Stern et al. in 1981 [17], and Kaufman et al. 
in 1984 [18]. 
Non-adaptive drug delivery systems proposed in the literature have 
serious limitations as they do not take into account the wide range of 
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patients’ drug sensitivities. A number of authors have investigated control 
drug infusion systems based on adaptive neural networks and Fuzzy logic. 
These topics are reviewed later on in chapter 6. 
1.2 Problem Definition 
Automatic feedback control plays an important role in modem 
medicine. Research in feedback strategies to control physiological systems 
started in the early 1950s. Bickford [19] used electrical activity of patients’ 
brain and the depth of anaesthesia index to actuate a feedback network 
which controls the dosage of anaesthetic administered to the patient. This is 
still an active research area, especially with regard to control of arterial blood 
pressure, as witnessed by the number of yearly publications. Many 
researchers have implemented automatic control system in order to maintain 
mean arterial pressure (MAP) and cardiac output (CO) by administering 
more than one drug. Most of the existing algorithms do not cover the wide 
range of patients’ response to the drugs. The challenge therefore, is to 
design control schemes that would give a robust and optimum performance 
despite variations in the patients’ responses to drugs. This research work will 
develop and investigate a number of approaches to solve this problem.  
1.3 Research Contribution 
The results of this research are expected to be helpful in 
understanding the contribution that computerized drug delivery systems can 
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make to improve patient care, especially hypertensive post-operative 
patients.  Delivery of optimal drug infusion rates is important in order to 
maintain blood pressure and cardiac output at desired levels during and after 
surgical operation. This research has investigated a number of control 
approaches and developed a neural network control scheme that works with 
a range of patient’s sensitivities to drugs. This scheme could be implemented 
in real time and tested in clinical trials. 
1.4 Aims and Objectives 
The aim of this thesis is to investigate, implement, test and compare 
both Single-Input Single-Output (SISO) and multi-loop feedback control 
strategies for regulating mean arterial blood pressure and cardiac output. 
The main objective of this research is to find the best solution to automatic 
drug delivery system. This is important as the uppermost concern of medical 
personnel is the quality of patients care.  
To achieve the optimal solution for the complications that may occur in 
postoperative patients, the objectives of my research are: 
 Investigate and design optimal control systems which could be suitable 
to implement in real time. 
 Design appropriate controllers to satisfy postoperative patient’s needs, 
such as the optimal drugs infusion rate, as required in several clinical 
situations in which it is necessary to infuse a drug in order to keep a 
patients’ blood pressure at certain limits. 
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1.5 Thesis Structure 
The rest of this thesis consists of six chapters. It is structured in a way 
that should make it easy to read. The outline of the structure can be 
summarized as follows: 
Chapter 2:  Literature Review: Presents the literature review of many 
researchers in relation to the problem of control of 
hemodynamic variables, such as MAP and CO. 
Chapter 3:  Control System and Tools:  Introduces a brief overview of the 
control systems and some of the schemes which have been 
applied to the patient response model and algorithms which 
have been used to obtain optimal responses. This chapter 
covers the optimisation technique which is implemented to 
obtain the optimal values of controller gains. 
 Chapter 4:  Control Schemes for Single-Input Single-Output (SISO) 
Model:  Introduces the patient response SISO model and 
algorithms which have been used, presents the optimisation 
tools used to achieve the optimal performance of PID and IMC 
controllers. The simulation results and the comparison between 
the two controllers are presented. 
Chapter 5:  MRAC for Multi-Input Multi-Output (MIMO) Patient 
Response Model: Presents the implementation and simulation 
results of the Model Reference Adaptive Control (MRAC) 
system to regulate patients’ MAP and CO by computing 
infusion rates of SNP and DPM 
Chapter 6:  Adaptive Multi-drug Neuro-PID Control Scheme for Blood 
Pressure Control: Presents the implementation and simulation 
results of the Neuro-PID control scheme, the procedure of 
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training the neural network, test and validation of the Neuro-
PID controller. 
Chapter 7: Conclusions and Future Work: Presents the concluding 
remarks and recommendations for future work. 
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Chapter 2.  
LITERATURE REVIEW 
2.1 Blood Pressure 
To understand how the various blood pressure lowering drugs work, 
one has to know about the complex ways in which blood pressure is 
controlled. There are two factors that influence blood pressure; cardiac 
output which is the quantity of blood being pumped by the heart, and 
peripheral resistance which is the resistance to flow. Resistance to flow is 
regulated by the size of the small arteries, which have muscle fibres in their 
walls, and can constrict and dilate. This means that when the blood pressure 
goes up it can do so in three ways, either by an increase in the cardiac 
output or by constriction of the arterioles, or by a combination of the two. In 
other words, blood pressure is the force applied against the walls of the 
arteries as the heart pumped blood through the body. So there are two ways 
of determining the pressure, by the force and quantity of blood pumped and 
the size and flexibility of the arteries. 
Blood pressure is measured in millimetres of mercury unit (mmHg). It 
is classified into two types of blood pressure, high blood pressure 
(hypertension), when the blood pressure is constantly higher than the 
recommended level and low blood pressure (hypotension), when the blood 
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pressure is constantly lower than the recommended level. Table 2-1 
presents the categories of blood pressure [20, 21]. 
Table 2-1: Blood Pressure Categories. 
CATEGORIES SYSTOLIC DIASTOLIC 
Hypotension ≤ 90 ≤ 60 
Normal 90 - 119 60 - 79 
Prehypertension 120 – 139 80 – 89 
High Blood Pressure (Hypertension) 
Stage 1 – Hypertension 140 – 159 90 – 99 
Stage 2 – Hypertension ≥160 ≥100 
2.2 Blood Pressure Medicines 
Blood pressure medicines work in different ways to regulate the 
patients’ blood pressure. Some eliminate extra fluid and salt from the body to 
lower the blood pressure; others reduce the heartbeat or relax and broaden 
the blood vessels. Often, two or more medicines work better than one. In this 
thesis we study and investigate two drugs related to the hemodynamic 
variables MAP and CO, namely Sodium Nitroprusside and Dopamine. 
2.2.1 Sodium Nitroprusside (SNP) 
SNP, brand name Nitropress is a potent rapid-acting vasodilator that 
works by relaxing the muscles in the blood vessels to help them dilate. 
Widening of arterial blood vessels decreases blood pressure. SNP is used 
for emergency treatment of hypertension, congestive heart failure, and to 
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keep blood pressure low during surgery. It is administered intravenously. 
SNP is a compound with the formula Na2[Fe(CN)5NO]·2H2O [22]. SNP 
breaks down in the blood and releases cyanide and nitric oxide. Nitric oxide 
enters the muscle cells in the walls of the blood vessels and causes them to 
relax. Cyanide is toxic in large quantities so SNP infusion rates must be kept 
brief or low, less than 2 µg/kg/min. 
2.2.2 Dopamine (DPM) 
DPM is an organic chemical in the catecholamine families, a class of 
compounds (drugs) that act by inotropic effect on heart muscle (causes more 
intense contractions) that, in turn, can raise blood pressure. At high doses, 
DPM may help correct low blood pressure due to low Systemic Vascular 
Resistance (SVR). It is available in only the generic form. It is used to treat 
hypotension, low cardiac output, and reduces perfusion of body organs due 
to shock, trauma, and sepsis. Also it increases Heart Rate (HR) and Stroke 
Volume (SV), leading to an increase in CO and MAP. 
2.3 Blood Pressure Control Using a Single Drug 
Since 1970s, several controllers have been developed to control the 
infusion rate of SNP in order to maintain the patients’ MAP for hypertension 
patients. These controllers have been tested in computer simulations and 
animal experiments. There does not seem to be any published clinical trials 
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on automatic drug delivery systems. Some of the controllers have been 
tested clinically and achieved satisfactory results. Yu in 2006 has 
recommended that, incorporating a supervisory algorithm can be helpful to 
improve the reliability and safety of the controller. The control strategies that 
have been investigated in the literature are Proportional plus Integral plus 
Derivative (PID), Adaptive control which includes Self-Tuning Regulator 
(STR), Model Reference Adaptive Control (MRAC), Multiple Model Adaptive 
Control (MMAC), and Rule-Based Control (RBC) in addition to Neural 
Network Control (NNC). A summary of blood pressure algorithms can be 
found in [23] and is shown in Table 2-2. 
Koivo, A.J in 1980, designed and employed the linear feedback 
controller to maintain the mean arterial blood pressure of dogs at desired 
level. The SNP were chosen as the antihypertensive drug to decrease the 
dogs’ blood pressure and a syringe pump device received the control signal 
as input. The open loop system is made up of a syringe pump and the 
mathematical model of the dog. The closed loop system was operated in the 
range of 100 to 170 mmHg of blood pressure and the desired level of the 
blood pressure was 0 to 30 mmHg [15]. 
Automated drug delivery systems based on a feedback controller 
have been implemented to control patients’ blood pressure. A computer-
based closed-loop feedback control system has been employed in the 
University of Alabama Hospital Cardiac Surgical Intensive Care Unit for the 
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surveillance and treatment of 8500 patients following heart surgery [24] and 
[25]. In [14] a system has been implemented to control the blood pressure of 
rabbits in the range of 20 mmHg by infusion of the anti-hypertensive drug 
Trimethaphan Camsylate (Arfonad). 
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Table 2-2: Summary of Blood Pressure Algorithms Reviewed [23]. 
ARTICLES CONTROL SCHEME 
CONTROLLER PERFORMANCE CONTROLLER TEST 
Settling Time 
(min) 
Overshoot 
(mmHg) 
Steady-state 
about the set-point (mmHg) 
simulation 
Animal 
Studies 
Clinical 
Studies 
 Slate et al. [26] and [7] Nonlinear PI <10  ±10 × × × 
 Arnsparger et al. [27] STR 2 30 10  ×  
 Mansour et al. [28] STR 5-20 <10 ±5 ×   
 Voss et al. [12] CAMAC 1.3-7.3 0-22 -4 to 9.8 × ×  
 Kaufmann et al. [18] 
MRAC (well-known 
time-constant and delay) 
<5  ±5 × ×  
 Pajunen et al. [29] 
MRAC (with time-varying 
parameters) 
<5 <15 ±15 ×   
 Polycarpou et al. [30] MRAC 5  ±10 ×   
 He et al. [31] MMAC <8 <5 ±5 × ×  
 Martin et al. [32], [33] and [34] MMAC <10 <10 ±5 × × × 
 Yu et al. [13] MMAC 3-10.5 0-12 ±5 × ×  
 Rao et al. [35] and [36] MMPC 12  ±5 × ×  
 Isaka et al. [37] Fuzzy Controller <3 <10 ±5 ×   
 Ying et al. [38] Fuzzy Controller   ±8 ×  × 
 Chen et al. [39] ANN 5 to 20  ±15 ×   
 Kashihara et al. [40] ANN 2  ±5 × ×  
Where, STR is Self-Tuning Regulator, CAMAC is Control Advance Moving Average Controller, MRAC is Model Reference Adaptive 
Control, MMAC is Multiple Model Adaptive Control and ANN is Artificial Neural Network. 
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Acute postoperative hypertension is a well-known complication of 
cardiac surgery and untreated hypertension may cause the patient condition 
to worsen. The right way to make the postoperative patients safe is by 
implementing automatic control to maintain the blood pressure at a desired 
level through infusion of drugs such as SNP. Several researchers have 
presented a number of methods for automatic control of blood pressure 
which have been tested on animals and humans [25], [41], and [42]. In 2005 
Zhu  [43] proposed a novel adaptive Proportional-Integral (PI) controller for 
hypertension control. White noise was added to the system to reflect the real 
situation and the system was tested on different patients with different drug 
sensitivities and time delays. 
SNP has a direct action on vascular smooth muscle which explains 
the rapid action within the first minute of infusion. In order to regulate the 
patients’ blood pressure and keep it at a desired level, the infusion rate of 
drugs need to be continuous. Auer, L et al. in 1981 have employed a 
microprocessor to control the infusion rate necessary to drive the patients’ 
blood pressure to the desired level within ±5% [44]. In addition, Koivo in 1981 
implemented a microprocessor based controller to control the mean arterial 
blood pressure in dogs using SNP as a vasodilator drug, the drug delivery 
system contained a microprocessor (Motorola 6800), Analog to Digital (A/D) 
and Digital to Analog (D/A) converters. The signal output of the 
microprocessor was utilized to drive a syringe pump to inject an optimal drug 
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infusion rate into the body of the dog. The closed loop system has been 
tested on dogs and performed over the range of mean arterial pressure from 
90 to 170 mmHg and over a period of time between 6 to 10 min. The 
proposed algorithm regulated the mean arterial blood pressure of dog within 
± 10 mmHg from the desired level [16]. 
Automatic control system of arterial blood pressure by infusion of SNP 
has been used for patients who had elevated blood pressure after open-
heart surgery at the Cardiac Surgical Intensive Care Unit at University of 
Alabama Hospital [24, 25]. A non-linear PID digital controller was tested on 
over 1700 patients. The investigations of the dynamics of the physiological 
response of patients to drug infusion are important for controller design. Also, 
the clinical experiences have shown that automatic control is safe and 
effective as compared to manual control [7].  
The closed-loop feedback control is necessary to use for patients who 
have open-heart surgery to adjust the drug infusion rate depending on the 
state of arterial blood pressure. This is also used to maintain the patients’ 
blood pressure near the desired level. Slate et al. in 1982 have reported that 
an adaptive multiple-mode multi-rate sampled data controller was designed 
using model based techniques, and implemented with a (LSI-11) 
microcomputer system [7]. 
Simulations and results of the nonlinear adaptive controller with 
experiments and clinical evaluations using a microcomputer implementation 
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show that system performance is improved as compared to the previous 
design. It is also noted that the system could be used in the operating room 
during and immediately after open-heart surgery [7]. 
A blood pressure control system has been developed based on the 
state predictive controller to reduce bleeding and avoid blood transfusion 
during open heart surgical operation using the drug Trimethaphan Camsilate. 
The dose response curves and the values of plant parameters have been 
used to derive a pure delay plus a first-order delay model. The accuracy and 
reliability of the system were evaluated by experimenting on dogs. The 
results have indicated the safety and stability of the system [45]. Before 
1995, many controllers were applied to blood pressure control such as PID 
controllers, optimal controllers, adaptive controllers and rule based 
controllers. Most of the controllers did not include the dead time of the blood 
pressure response to drugs and also could not determine the drug infusion 
rate from the current blood pressure so researchers have suggested taking 
the dead time into account to improve the drugs’ effects on the system 
stability and the transient response [41], and [9]. 
PI adaptive control has been implemented in [5] to maintained MAP at 
desired level using the vasoactive drug SNP with white or colored noise as 
disturbance. The adaptive controller can modify its behaviour in response to 
changes in the process dynamics and the character of the disturbances. 
During the simulation, the initial blood pressure was 150 mmHg and the 
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objective of the controller was to decrease blood pressure by 50 mmHg 
within ±15 mmHg. The system was disturbed by the noise. The patients’ 
sensitivity to drug has effects on the system response, such as MAP and 
SNP infusion rate. The simulation results showed that the control system 
which has been implemented was able to regulate MAP within the suitable 
time [5]. 
An Internal Model Control (IMC) has been introduced in [46], and was 
defined for single input-single output, discrete-time systems. The basic 
structure of this IMC is shown in Figure 2.1. The controller has been 
implemented to maintain the patients’ blood pressure at desired level using a 
single drug (SNP). The IMC system gain K1 is the only parameter that may 
have an influence on system stability. The system gain was computed using 
an adaptation law described in [8]. In order to produce an optimal drug 
infusion rate, a genetic algorithms (GAs) optimization technique method 
based IMC has been developed and implemented. The IMC has been 
optimised using GAs optimization technique method as a tool of one of the 
Simulink Response Optimisation Techniques (SROT) method. The system 
has been tested on three types of patient, with different sensitivities to SNP 
in the presence of disturbances [47]. The GAs optimization technique 
method from simulink response optimisation toolbox was utilized to tune the 
system gain [48]. The simulation results of this system displayed good 
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performance and have achieved the optimal infusion rate for different kind of 
patients [8], [47], [26]. 
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Figure 2.1: Basic Structure of Internal Model Control (IMC). 
The comparative study of optimization algorithms for IMC based blood 
pressure control has been done [49]. Six methods of optimization techniques 
were compared to reveal the merits and capabilities of the algorithms. The 
study demonstrate that the traditional gradient descent method which has 
been utilized in [8] offered the weakest performance while the GAs 
optimization technique method achieved the shortest execution time to 
optimise the system parameters [49] and also has been utilized in the 
optimal IMC control of a pneumatic servo system [50]. 
Self-tuning control strategies, which synthesize directly or indirectly 
the controller parameters online have been used to deal with changes in the 
process characteristics. The self-tuning regulator was first introduced by 
Astorm and Wittenmark in 1973 [51]. In [17] a self-tuning regulator was 
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implemented to automate blood pressure control. The self-tuning regulator is 
designed to maintain reliable performance under a variety of conditions. 
A non-adaptive controller has been used to automate blood pressure 
regulation and from several researchers this algorithm has proven the safety 
of closed-loop control for high blood pressure. But in order to control 
hemodynamic variables such as MAP and cover the wide range of patient 
characteristics, adaptive control has been implemented with parallel least-
squares estimation routines to regulate MAP using a single drug SNP [52]. 
Behbehani et al. in 1990 presented an adaptive control scheme and reported 
that this algorithm is suitable for regulating the MAP using SNP [53]. 
Stochastic adaptive control is the control of a partially known or 
completely unknown stochastic system. A physical system is often subject to 
perturbations and a model for a physical system is only an approximation so 
there are unmodeled dynamics. These perturbations or unmodeled dynamics 
are often described by noise entering the model. For physical systems, it is 
often important or even necessary to control the system to have some 
desirable behaviour.  
As a result of the need for automated drug infusion control, many 
studies have been made to develop an automatic control system to maintain 
blood pressure within physiological limits. Stochastic adaptive controllers 
have been developed and applied to control dogs’ blood pressure. Two 
drugs have been used, one is LevophedTM named as Norepinephrine (NE) 
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was infused to elevate the blood pressure and the other is SNP to reduce the 
blood pressure [27]. 
In [28] the comparison between two algorithms indicated that the one-
step-ahead minimum adaptive controller has the better performance of 
producing a smoother control action with less oscillation in the infusion rate 
than minimum variance adaptive controller. The important advantage of their 
controller, is that it can adjust the systems’ parameter online depending on 
the changes in the circulatory state within eight steps as presented in the 
cycle of program control loop as shown in Figure 2.2, see [28]. 
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Figure 2.2: Graph of Program Control Loop. 
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Many researchers have tried to demonstrate the performance of 
Model Reference Adaptive Control (MRAC) for regulates of hemodynamic 
variables. This controller has been implemented to regulate the infusion rate 
of SNP in order to regulate blood pressure [18]. 
The Multiple Model Adaptive Control (MMAC) has been implemented 
and tested on animal (dogs). In the treatment of hypertension, infusion of 
SNP was automated using MMAC in order to regulate the patients’ blood 
pressure. The following performance criteria, which have been introduced by 
Slate in [26], were used to evaluate the controller in [31]: 
 Undershoot not more than 10 mmHg. 
 Settling time from 5 to 10 mines. 
 Steady-state error within ±5 mmHg. 
In addition, other researchers have proposed MMAC to regulate the 
blood pressure. Martin et al. in 1987 have presented this algorithm with pole-
placement, via state-variable feedback to control blood pressure using SNP; 
also they have employed Proportional-Integral (PI) control to obtain zero 
steady-state error. The authors reported that a wide range of patient 
characteristics were controlled including noise which is used to model the 
variance of sudden changes in patients’ blood pressure up to 4 mmHg [32]. 
An adaptive controller needs supervisory functions in order to function 
well in changeable system environment such as during cardiac surgery. The 
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supervisory functions guarantee that adaptation only is performed when 
proper excitation is available. Due to the complexity of arterial pressure 
control during cardiac operation, in 1992, Martin et al. have developed and 
implemented a Supervisory Adaptive Controller (SAC) in closed-loop control 
in order to regulate MAP using SNP. This controller includes a pole-
placement and proportional-plus-integral regulator, which has been used to 
deal with aggressive step response characteristics. The multiple-model 
adaptation was employed to guarantee fast and stable adjustments for any 
changes in patient parameters, and the supervisor was used to provide 
safety and efficiency of control in the presence of disturbances during 
cardiac operation [34]. 
Fuzzy control based on the general-purpose fuzzy logic production 
system has been implemented to regulate patients’ MAP by controlling the 
infusion rate of antihypertensive drugs such as SNP. In most studies, the 
patients’ model has been described by a first-order linear model with two 
time delay, one time-delay represents the initial transport delay and the other 
represents the recirculation time delay. This patient model has been used 
with different patients’ sensitivities to SNP [7, 26, 54]. In 1990 Ying and 
Sheppard [55] presented and implemented a fuzzy controller to regulate 
MAP of pigs by infusion of SNP. The fuzzy controller was designed by using 
experts’ knowledge and experience without any mathematical models 
involved. 
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Many researchers have focused on the complication problems of 
postoperative hypertension in cardiac patients; the automatic drug delivery 
control system is desirable to achieve optimal drug infusion rate. Feng et al. 
in 2006 have designed and implemented control system using adaptive PI 
and Fuzzy controllers in order to reduce harmful oscillations in MAP and 
control the infusion rate of SNP depending on the patients’ conditions [56]. 
2.4 Blood Pressure Control Using Multi Drugs 
Research into control of hemodynamic variables such as blood 
pressure was started by Slate et al. in 1979 using a PID controller in order to 
lower MAP by infusing SNP [57]. Since then, more complex control 
algorithms have been used in order to automate regulation of hemodynamic 
variables. In 1993 Isaka and Sebald presented an extensive review of SISO 
systems, and they drew attention to more important issues of safety and 
robustness when dealing with multiple drugs to control more than one 
hemodynamic variable [9]. 
Adaptive control has been used by Martin et al. [34] and Kwok et al. 
[58] in order to regulate blood pressure during surgery. In addition many 
research efforts have been made to regulate MAP and cardiac output (CO). 
Serna et al. in 1983 reported on the simultaneous control of CO and MAP 
using DPM, a drug used to increase MAP and CO on the other hand SNP 
was used to increase CO and decrease MAP. They designed a computer 
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based controller which combines adaptive control schemes and supervisory 
functions. Their simulations and animal experiments have indicated that 
pole-placement self-tuning controllers are potentially useful in adjusting the 
infusion of sodium nitroprusside when infused as a single drug or when 
combined with another drug such as dopamine [59]. 
Lau et al. in 1984 have presented a comparison of the utilization of 
different types of adaptive controllers which have been used to adjust the 
infusion rate of two drugs, DPM and SNP, in order to control SVR and CO. 
The controller’s robustness was tested during simulation using three values 
of the system sensitivity parameters. These values represented the patients’ 
sensitivity to drugs [60]. 
In clinical practice, the control of patients’ blood pressure is commonly 
treated by multiple drug infusions. An adaptive control algorithm has been 
implemented by McInnis and Deng in 1985 to control MAP and Central 
Venous Pressure (CVP) using both an inotropic agent and a vasoactive 
agent. An inotropic drug was utilized to increase the CO, MAP and CVP, and 
a vasodilator drug to decrease the afterload. Their simulation results have 
demonstrated CO increased by 25% [61]. 
In 1986 the simultaneous control of MAP and CO in anesthetized 
dogs was presented by Voss et al. [62]. The moving average controller and a 
modification of the minimum variance self-tuning controller was used to 
regulate the infusion of both vasodilator drug SNP, and a positive inotropic 
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agent, Dobutamine (DBT). Their simulation results have demonstrated the 
performance of the system. MAP was decreased to within 5 mmHg of the 
desired level with range of overshoot from zero to 22 mmHg, and CO was 
increased to within 0.05 l/min of the desired level in 11.8 minutes with range 
of overshoot from zero to 0.18 l/min. Also CO could not reach the desired 
level as set-point for 32 minutes with maximum infusion rate of DBT, on the 
other hand MAP was maintained at the desired set-point level with range of 
average error from -4 to -9.8 mmHg after 10 minutes of the transient control 
period, and CO reached the value of desired level after 10 minutes with 
range of average error from -0.026 to -0.05 l/min [62]. Voss et al. research in 
1987 demonstrated the implementation of a multivariable drug delivery 
system was able to achieve the optimal performance but was not able to 
show adequate evidence for clinical applications [12]. Their simulation results 
are presented in the Table 2-2.  
Barney and Kaufman in 1990 presented the MRAC implementation to 
concurrently control MAP and CO by infusing two drugs, DPM and SNP. The 
adaptation weights for “a two-input two-output” Multi-Input Multi-Output 
(MIMO) system was developed and utilized to update the parameters. The 
controller was tuned using 6×6 time invariant weighting matrices. The 
controller was first tuned using a single-input single-output system and then 
was tuned using a two-input two-output system. The weights which were 
represented as matrices T and T were computed for one-input one-output 
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system with time delays and drug infusion limits and then for two-inputs two-
outputs [63]. 
In 1990, Yu et al. developed a computer model to approximate the 
hemodynamic responses of inotropic drug such as DPM and vasodilator drug 
such as SNP in the case of acute left ventricular pump failure. This model 
was proposed to support the design of a multiple drug delivery infusion 
system. A non-linear electrical analog circuit has been utilized with baroreflex 
feedback to simulate the circulatory system. The model was programmed by 
PASCAL and implemented on an IBM AT microcomputer. This model needs 
more development to compute the hemodynamic online because of the large 
number of equations required to be solved per heartbeat. DPM was used to 
reduce renal vascular resistances at low infusion rate. With this model the 
response to DPM cannot be simulated because the systemic resistances 
have been lumped into a single element [10]. 
In order to regulate MAP and CO in congestive heart failure by 
updating the infusion rates of SNP and DPM, Yu et al. in 1992 have 
designed and employed multiple-model adaptive predictive control. The 36 
linear small-signal models have been implemented to span the entire space 
of anticipated responses. The model is reduced to six models with the 
highest probabilities used in the control calculations to reduce computation 
time. The algorithm was based on MMAC and utilized model predictive 
controllers to provide reliable control in each model. The controller has been 
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tested and evaluated on laboratory animals. The simulation results have 
demonstrated the controller performance with 3 to 10.5 minutes of settling 
time and 0 to 12mmHg overshoot, and within ±5 mmHg of steady-state [13]. 
In 1998, Palerm et al. presented the implementation of a multivariable, 
indirect-adaptive pole placement controller to regulate MAP and CO by 
adjusting the infusion rates of SNP and DPM. The control objective was to 
drop MAP by 20 mmHg from the value of 119 mmHg and to drop CO by 5 
ml/min/kg from the value of 131 ml/kg/min. The system still needs more 
development to cover more possible system variations [64]. 
Linkens and Nie in 1992 presented control systems and fuzzy 
decision-making in order to deal with the problem of multivariable control of 
hemodynamic variables such as MAP and CO. The application of the 
proposed algorithms was to regulate simultaneously both CO and MAP by 
infusing the vasoactive drug SNP and an inotropic drug DPM [65]. 
The congestive heart failure is one of the heart problems and in this 
case Gopinath et al. in 1995 presented a multirate Model Predictive Control 
(MPC) design for regulating MAP and CO by controlling the infusion rate of 
SNP and DPM. A selective linearization technique was introduced to reduce 
computation time. The novel Rule-Based Override (RBO) to the MPC 
controller was implemented to avoid extremely slow responses of the initial 
DPM infusion [66]. 
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In 1998, and 2000 Huang et al. presented the development and 
validation of a fuzzy-logic-based automated drug delivery system using a 
nonlinear canine circulatory model. This system was implemented for 
managing the hemodynamic status of animal using four drugs, DPM, 
phenylephrine (PNP), SNP and NTG. The algorithm was composed of three 
parts, Fuzzy Decision Analysis Module (FDAM) which was utilized to 
appraised the status of the patient and to choose a suitable therapeutic 
strategy after the evaluation, a Hemodynamic Management Module (HMM) 
which was employed to determine the correct drug dosage based on the 
current states of the patient, and a Therapeutic Assessment Module (TAM) 
used to schedule drug delivery by evaluating several parameters, and 
considers each case individually as recommended by the FDAM [67, 68]. 
The indirect adaptive control scheme based on recursive identification 
and linear quadratic regulation has been implemented in 1999 by Achuthan 
et al. on a nonlinear canine model to control the infusion rates of DPM, SNP 
and NTG in order to maintain MAP and CO. The recursive identification was 
conventional Recursive Least Squares (RLS) and a modified version (MRLS) 
to follow large parameter changes [11].  
The complication problem in heart disease has different categories 
such as congestive heart failure, post-operative hypertension, and sepsis 
shock. From this point, in 1999 Rao et al. have presented a model predictive 
controller and tested it on a nonlinear canine circulatory model to regulate 
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the hemodynamic variables considering the critical care conditions. The 
controller has been tuned on a linear plant model and tested on a nonlinear 
model. This algorithm has been employed to regulate MAP, Mean Pulmonary 
Arterial Pressure (MPAP) and CO using SNP for arterial vasodilation and 
DPM to enhance cardiac performance. PNP was used as an arterial 
vasoconstrictor and NTG is a venodilator. Their simulation results have 
demonstrated a settling time of 10 minutes for MAP and MPAP and from 15 
to 20 minutes for CO [69]. 
In 1999, Rao et al. employed a multiple model predictive controller to 
regulate MAP and CO of a mongrel dog by controlling the infusion rate of 
SNP, DPM and PNP. The simulations were conducted in order to regulate 
the outputs within a range of values [70]. 
Design of robust control is a challenging task because of 
complications such as nonlinear systems’ behaviour, significant changes in 
dynamics from patient to patient, and variations in the patients’ response to 
drugs. Ozcelik and Palerm research focused on this problem [71]. They 
developed a Direct Model Reference Adaptive Controller (DMRAC) to deal 
with uncertainty in time delays and the parameters of the patients’ model 
using a two-input two-output first order system with delays which was 
developed by Yu et al. in 1992. The controller they developed was based on 
a simple adaptive control scheme of MIMO plants first proposed by Sobel et 
al. in 1979 [13, 71-73] respectively. 
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Fuzzy logic control has been implemented by Huang et al. In 1998, 
and 2000 [67, 68] to manage the parameters of hemodynamic states using 
multiple drugs. The controller has been designed using three components: 
 A Fuzzy Decision-Making Module (FDMM) used to recommend a 
therapeutic strategy for the patients’ case based on the Cardiac Index 
(CI), the Systemic Vascular Resistance Index (SVRI), and the Pulmonary 
Vascular Resistance Index (PVRI). 
 A Fuzzy Hemodynamic Control Module (FHCM). From the current 
patients’ states of MAP, MPAP, and CO, this module is used to change 
the drugs dosage depending on the current states of the patient. 
 TAM is employed to schedule drug delivery based on the patients’ case 
from the FDMM and the drug changes which has been determined by 
the FHCM. 
In 2003, a Fuzzy-logic based automatic control system was 
implemented by Bauernschmitt et al. to observe and handle any changes in 
hemodynamic variables such as MAP, CO, CVP and SVR using the drugs 
noradrenaline, dopamine and nitrates. The hemodynamic parameters and 
the drugs were linked by knowledge-based rules in a fuzzy-logic system [74]. 
In recent years, there was active research into automated control 
systems for regulation of MAP and CO using multi drugs. In 2003, Rao, 
Aufderheide, and Bequette presented experimental studies on multiple 
model predictive control system for regulating MAP and CO using SNP and 
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DPM for canines under the influence of two different anesthetics, isoflurane 
and halothane. They also presented the comparison with manual control of 
MAP and CO [36]. 
In 2006 Kashihara presented the implementation of a Multiple 
Adaptive Predictive Control Based on Neural Networks (MAPCNN) to regulate 
the nonlinear responses of hemodynamic variables MAP and CO in acute 
heart failure using an inotropic agent such as DBT and a vasodilator agent 
such as SNP. The algorithm has been designed and evaluated in actual 
heart failure of a dog under unexpected changes of the patients’ sensitivities 
to drugs [75].  
The regulation of hemodynamic variables such as MAP and CO is 
extremely desirable during operation and in post cardiac operation. Kumar et 
al. in 2009 presented a fuzzy Proportional-Derivative (PD) controller to 
regulate MAP and CO by infusing three drugs DPM, SNP and phenylephrine 
(PHP). Figure 2.3 displays the block diagram of the Fuzzy Control (FC) 
system, with 25 rules as shown in Table 2-3. The relationship between CO 
and HR is explained by Equation (2.1) and Equation (2.2). The problem 
which faced Kumar et al. is the mathematical models for different drug 
actions. To improve the performance of the proposed controller, they 
modified the controller as "self-organized Fuzzy Logic Controller (FLC)" or as 
a neuro fuzzy controller [76]. 
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CO = SV × HR (2.1) 
 
where,  CO is the cardiac output. 
SV is the stroke volume. 
HR is a heart rate. 
SV = EDV − ESV (2.2) 
where,  EDV is the End Diastolic Volume. 
ESV is the End Systolic Volume. 
MAP
CO
Fuzzification
Error e(nT)
Error
Change ce(nT)
Fuzzy Expert 
System
Defuzzification
Process
de(nT)
dt
+
 -
+
 
-
Set Point
 
Figure 2.3: Block Diagram of Fuzzy Control System. 
Table 2-3: Rule Based for The Fuzzy Controller [76]. 
ce(nT) 
e(nT) 
NB NM NS Z PS PM PB 
NB - - - - - - - 
NM - - - - - - - 
NS - - NB NB - - - 
NO - - NO NO Z - - 
PO - - PS PS Z Z NO 
PS - - PS PS PS PO Z 
PM - - PB PM PM PS PB 
PB - - PB PS PB PM PB 
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Where, e(nT) represent the error and ce(nT) represent the change of error, 
and the terms which have been considered are: 
NB : Negative Big.   NM : Negative Medium. 
NS : Negative Small.   Z : Zero. 
NO : Negative Zero.   PO : Positive Zero. 
PS : Positive Small.   PM : Positive Medium. 
PB : Positive Big. 
In 2009, Sugimachi et al. presented the controlling of multiple 
hemodynamic variables such as CO, Right Atrial Pressure (RAP) and Left 
Atrial Pressure (LAP) with multiple cardiovascular drugs such as Dobutamine 
(DOB), SNP, Dextran (DEX) and Furosemide (FM) [77]. Their studies have 
shown direct control of hemodynamic variables is unfeasible even with 
different control engineering methods. The problem is complicated due to 
anomalies of cardiovascular properties, including pump function, vascular 
resistance, and blood volume. They used the extended version of Guyton’s 
circulatory equilibrium framework to identify these properties. This version 
has also been presented in 2004 and 2005 by Uemura et al., [78, 79], Figure 
2.4 Figure 2.4 shows the extended version of Guyton’s model see [77]. 
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Figure 2.4: Extended Version of Guyton’s Model [77]. 
2.5 Summary 
This chapter has covered most of the control algorithms that have 
been implemented by many researchers to regulate the hemodynamic 
variables using single and multiple drugs. As this literature survey revealed, 
control of MAP and CO is an active research area and a challenging task. 
In next the chapters design, development, implementation and 
simulations results of a number of SISO and MIMO control strategies will be 
presented using the drugs SNP and DPM to regulate MAP and CO. 
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Chapter 3.  
CONTROL SYSTEM AND TOOLS 
3.1 Introduction 
In general a feedback control system consists of subsystems and 
processes (or plants) assembled for the purpose of obtaining a desired 
output with desired performance, given a specified input. Control has 
become essential for design of experimental apparatus and instrumentation 
which is usually used in sciences and it will be more important in the future. 
The principles of control have an impact on different fields such as 
economics, biology, and medicine. [80].  
A control system is an interconnection of some components utilized to 
maintain the optimal or desired result. The assortment of components could 
be a part of a control system as electrical, electronic, mechanical, human, or 
any grouping of these. The optimal result of the control system is a value of 
the variable in the system, for example, the speed of DC or AC motor in 
plant, the temperature of the heating system in the house, the level of liquid 
in a tank, or the blood pressure in patients’ circulatory system. The output of 
the control system is called the controlled or manipulated variable [81]. The 
component or process which needs to be controlled can be represented by a 
block as shown in Figure 3.1. 
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PROCESS
Input Output
 
Figure 3.1: General BLock Diagram of a Process in input/output Form. 
To maintain a physical quantity, such as pressure, flow or temperature 
at a desired level during a technical process, this quantity can be controlled 
either by means of open loop control or closed loop control. The control 
systems are generally classified as either open loop control system or close 
loop control system. 
 Open loop control system (without feedback). 
 Closed loop control system (with feedback). 
3.1.1 Open Loop Control system 
An open loop is not self adjusting, it is controlled by its input only, and 
its input and output are unrelated. Open loop control has no feedback and 
therefore is incapable of making automatic adjustments. This is the reason 
an open loop control system is not suitable for use as a complex control 
system. An open loop control system utilizes a controller or control actuator 
to obtain the desired system response without feedback. Figure 3.2  shows 
the general structure of open loop control system [82]. 
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Plant Being 
Controlled
Open-Loop
Controller
Input Signal Output Signal
 
Figure 3.2: General Structure of Open Loop Control. 
3.1.2 Closed Loop Control System 
In a closed loop control system there is some items between the input 
signals (reference, or set point) and controlled the output signals. And there 
is one item such as a measurement or sensor device which uses the output 
signal as feedback to make the comparison and produces the error signal to 
be the input of the controller. A feedback control system often uses a 
function to maintain a relationship between the system input, called 
reference input and system output or feedback signal to control the process. 
The differences between input signal and output signal through feedback is 
the error signal. The general structure of a closed loop control system is 
shown in Figure 3.3 [82]. 
Controller Process
Measurement device
Error SignalInput Output
+-
 
Figure 3.3: General Structure of Close Loop Control System. 
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3.2 Control Algorithms 
The objective of a controller design is to ensure that the resulting 
system is stable, achieves its performance objectives, and is robust to 
disturbances such as changes in workloads. These objectives are achieved 
by properly designing feedback loops. Controller design is a three-step 
process: 
 System modelling, i.e. the definition of a model. 
 System analysis, i.e. the study of the model behaviour. 
 Controller design. The design technique is the algorithm or methodology 
used within the control algorithm in order to generate the control action 
variables from the measured variables. 
3.2.1 PID Control 
PID control also referred to as three-term control is widely used in 
many fields such as process industries, economics, biology, and medicine 
because of its simple structure and robustness to modelling errors. It has a 
long-term record of giving satisfactory performance. In process control, PID 
control is applied in more than 95% of the control loops [83]. In the past 
decades there are many researchers dealing with the method of PID 
controllers tuning for different processes. The general PID control law is 
given by Equation (3.1): 
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u(t) = Kpe(t) + Ki ∫e(t)dt + Kd
de(t)
dt
t
0
 (3.1) 
where: 
u(t) : Control signal. 
Kp : Proportional gain, a tuning parameter. 
Ki : Integral gain, a tuning parameter. 
Kd : Derivative gain, a tuning parameter. 
e : Error between setpoint and process output. 
In conventional PID control, once well-tuned gains are obtained, the 
controller usually exhibits good performance. However, when the dynamic 
characteristics of the system are time dependent or the operating conditions 
of the system vary, it is necessary to retune the PID and PI parameters 
again. The manual tuning of controllers, which requires optimization of the 
parameters, is a time-consuming task. To deal with this difficulty, much effort 
has been invested in developing systematic tuning methods. Many of these 
methods depend on knowledge of the plant model. Some of these tuning 
methods have been described by Astrom et al. in 1993 [84].  
In this thesis the genetic algorithms (GAs) optimization technique 
method is used to obtain optimal values for the PID gains. 
The parameters of the PID controller can be adjusted by experiment, 
trial and error or by using one of the many tuning techniques. Table 3-1 
shows how the PID gains affect system response, stability and steady-state 
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error. In the conventional PID control algorithm, the proportional (P), integral 
(I) and derivative (D) terms are placed in the forward loop. These PID 
controllers are suitable for controlling stable processes with small time 
delays. 
Table 3-1: The Rules for Tuning PID Controller Parameters. 
Parameter Speed Of Response Stability Accuracy 
If Kp increases increases Deteriorates Improves 
If Ki increases Decreases Deteriorates Improves 
If Kd increases increases Improves No impact 
 
3.2.1.1 Open-Loop and Closed-Loop Control Example 
The characteristics of a PID controller are presented in Table 3-2 and 
explained with some examples. Equation (3.2) describes a second order 
transfer function model of a plant, and the open-loop and close-loop Simulink 
control diagrams without a controller are shown in Figure 3.4, and Figure 
3.5. The outputs of the two systems are depicted in Figure 3.6. The plant 
output signal cannot reach the desired amplitude of (1) without the use of a 
controller.  
Plant transfer function:- 
u(t) =
Y(s)
X(s)
=
1
s2 + 10s + 20
 (3.2) 
Where, X(s) is the input of the system and Y(s) is the output of the system. 
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Table 3-2: The Characteristics of a PID Controller. 
Parameter Rise Time Overshoot Settling Time Steady-State Error 
If Kp increases Decreases increases Small Change Decreases 
If Ki increases Decreases increases Increase Eliminates 
If Kd increases Small Change Decreases Decreases Small Change 
 
1
1
s  + 10 s+ 202
Step Transfer Function
Output
 
Figure 3.4: Simulink Model of Open-Loop Control System. 
1
1
s  +10s+202
Step
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Transfer Function
 
Figure 3.5: Simulink Model of Closed-Loop Control System. 
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Figure 3.6: Open-Loop and Close-Loop Control System Response without Controller. 
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3.2.1.2 The Objectives of Designing a PID Controller 
In general we have to obtain an open-loop system response and from 
that we can determine what needs to be improved. The parameters of the 
controller can be adjusted to achieve the optimal system response as shown 
in Tables 3-1 and 3-2. Increasing the proportional gain will improve the rise 
time. The overshoot and settling time can be improved by increasing the 
derivative gain. Using an integral term will eliminate the steady-state error. 
However, system stability may suffer so careful tuning of the integral gain is 
required. When dealing with systems with transport delay, derivative action 
does not give good performance so it is better to use PI terms only. 
Derivative action amplifies noise in the output so filtering should be applied 
before using it. 
3.2.1.3 Proportional Control – Example 
The proportional gain (Kp) reduces the rise time, increases the 
overshoot, does not affect settling time much, and decreases the steady-
state error but does not remove it entirely. In this simulation example we 
used a proportional controller (P). Figure 3.7 shows the Simulink diagram of 
the system with proportional control. The system responses with different 
value of Kp, 100, 200 and 300, are depicted in Figure 3.8. 
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Figure 3.7: Simulink Block Diagram of Control System with P Controller. 
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Figure 3.8: System Responses Using P Controller. 
3.2.1.4 Proportional - Derivative Control – Example 
The derivative gain (Kd) reduces both the overshoot and the settling 
time, it also produces a small change in both the rise time and steady-state 
error. In this example a PD controller was simulated as shown in Figure 3.9. 
The system responses are displayed in Figure 3.10 with different values of 
Kd, 10, 20 and 30 and with Kp fixed at 300. 
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Figure 3.9: Simulink Block Diagram of Control System with PD Controller. 
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Figure 3.10: System Responses Using PD Controller. 
3.2.1.5 Proportional - Integral Control – Example 
The integral term decreases the rise time, increases both the 
overshoot and the settling time, and eliminate the steady-state error. Integral 
action is always used with proportional term P. Figure 3.11 shows the 
simulated PI controller and Figure 3.12 displays the system responses with 
different values of Ki, 70, 85 and 100 and a fixed value of Kp at 30. 
1
1
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Kd
 
CHAPTER 3. – CONTROL SYSTEM AND TOOLS  
 
44 
 
 
1
1
s  + 10 s+ 202
PI-Controller
1
s
Kp
Ki
Step
Transfer Function
Output
 
Figure 3.11: Simulink Block Diagram of Control System with PI Controller. 
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Figure 3.12: System Responses Using PI Controller. 
In addition, there are different types of PID controller structures such 
as, parallel (non-interactive) and serial (interactive) that are fully explained by 
Vukic et al 2002 in [85]. The terms of the parallel structure have different 
forms as shown in Figure 3.13, Figure 3.14, Figure 3.15 and Figure 3.16. 
They also have different ways of dealing with the control signal. The PID 
control laws are given in Equation (3.3) and Equation (3.4), where r is the 
reference signal, e is the error signal, u is the control signal or plant input, 
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and y is the output signal as shown in Figure 3.13, Figure 3.14, Figure 3.15 
and Figure 3.16. 
u(t) = K [e(t) +
1
Ti
∫e(t)dt + Td
de(t)
dt
t
0
] (3.3) 
or 
u(t) = Kpe(t) + Ki ∫e(t)dt + Kd
de(t)
dt
t
0
 (3.4) 
Plant+
+
+
+
-
P
I
D
Reference 
Signal (r) Error (e)
Controlled 
Signal (u) Plant Output (y)
Feedback Signal
 
Figure 3.13: Block Diagram of PID Controller form Parallel Structure. 
Another PID structure is shown in Figure 3.14 where the P and I 
terms of the PID controller have the error signal as input, and the derivative 
term is in the feedback path. Using derivative of the output signal is more 
robust in practical implementations [85] since the discontinuity in a step 
change reference signal could produce a large control signals (u). The output 
does not change instantaneously for a step input so a smoother signal is 
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produced by taking the derivative of the output. The PI-D control law is 
described by Equation (3.5), or Equation (3.6). 
u(t) = K [e(t) +
1
Ti
∫e(t)dt − Td
de(t)
dt
t
0
] (3.5) 
or 
u(t) = Kpe(t) + Ki ∫e(t)dt − Kd
de(t)
dt
t
0
 (3.6) 
Plant+
+
+
-
P
I
D
Reference 
Signal (r) Error (e)
Controlled 
Signal (u) Plant Output (y)
Feedback Signal
-
 
Figure 3.14: Block Diagram of PI-D Controller form Parallel Structure. 
In the I-PD scheme shown in Figure 3.15, the input to the integral 
term (I) is the error signal. An abrupt change in the reference signal will not 
affect the proportional term (P) and derivative term (D), since these two 
terms work on the plant output (y). The control law of the I-PD is given in 
Equation (3.7), or Equation (3.8). 
u(t) = K [
1
Ti
∫e(t)dt − y(t) − Td
dy(t)
dt
t
0
] (3.7) 
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or   
u(t) = Ki ∫e(t)dt − Kpy(t) − Kd
dy(t)
dt
t
0
 (3.8) 
Plant
+
+
- I
P D
Reference 
Signal (r) Error (e)
Controlled 
Signal (u) Plant Output (y)
Feedback Signal
-
-
 
Figure 3.15: Block Diagram of I-PD Controller Form Parallel Structure. 
The series interacting form of the PID controller is shown below in 
Figure 3.16. The control law is given by Equations (3.9) and (3.10). 
u(t) = K [e1(t) +
1
Ti
∫e1(t)dt
t
0
] (3.9) 
where  
e1(t) = [e(t) + Td
de(t)
dt
] (3.10) 
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Figure 3.16: Block Diagram of D-PI Controller Form Serial Structure. 
3.2.2 Internal Model Control 
The structure of the IMC system consists of three terms as shown in 
Figure 2.1 of chapter two. The first term is the internal model which can be 
used to predict the process outputs. The second term is the internal model 
loop which uses the difference between the process output and the internal 
model output. Finally, the third term is the controller which uses the error to 
compute the future values of the process outputs. The difference between 
the output of the internal model and the process output is fed back to 
produce the error (e), used by the controller. This helps reduce the effect of 
disturbances on the system [86]. 
The IMC is applied to stable nonlinear systems described by linear 
parameter-varying models. Many researchers had proved the good 
performance of the Internal Mode Control method. It is an important 
nonlinear controlling approach to system and had been discussed by many 
researchers. 
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3.2.3 Adaptive Control 
There are many dynamic systems having constant or slowly-varying 
uncertain parameters. For example robot manipulators may carry large 
entities with unknown inertial parameters. Fire-fighting aircraft may 
experience significant mass changes as they load and unload large 
quantities of water. Adaptive control is a solution for controlling such 
systems. The basic strategy in adaptive control scheme is to estimate the 
uncertain plant parameters or corresponding controller parameters on-line 
based on the measured system signals and then incorporate the estimated 
parameters in the control input computation. Due to this, adaptive control 
system can be referred as a control system with on-line parameter 
estimation.  
Adaptive control had been introduced in the early 1950's with the 
design of autopilots for high-performance aircraft, which were operated at a 
large range of speeds and altitudes. Therefore, they faced large parameter 
variations. Adaptive control was suggested as a new way of automatically 
adjusting the controller parameters against the aircraft uncertain dynamics. It 
maintains consistent performance of a system in the presence of uncertainty 
or unknown variation in plant parameters. Since parameter perturbation 
occurs in many practical problems, therefore adaptive control has been 
successfully applied in many control applications for example in robot 
manipulation, ship steering, Aircraft control, Process control, power systems, 
biomedical engineering etc. [87].  
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3.2.3.1 Adaptive Controller Design 
An adaptive controller is different from conventional controller (non-
adaptive) in that the controller parameters are variable, and there is a certain 
mechanism for adjusting these parameters on-line. Generally, adaptive 
controller is superior to robust controller in dealing with parameters 
uncertainties. It requires slight or no a priori information about the unknown 
parameters, whereas a robust controller usually needs sufficient information 
about parameter bounds. However, a robust controller has some significant 
features which an adaptive controller does not contain, such as its ability to 
deal with disturbances and unmodeled dynamics. Such characteristics 
essentially are combined with adaptive control to increase robustness. There 
are mainly two techniques for constructing adaptive controllers: one is the 
model-reference adaptive control (MRAC) method and the other is the self-
tuning method. The block diagram of MRAC scheme is shown in the Figure 
3.17. It consists of four parts. The plant containing unknown parameters may 
be linear or non linear. 
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Figure 3.17: A model-reference adaptive control. 
The reference model is used to specify the desired output of the 
control system. The feedback control law should be designed in such a way 
that when the plant parameters are exactly known, the corresponding 
controller should make the plant output identical to that of the reference 
model. In case when the plant parameters are unknown, the adaptation 
mechanism will adjust the controller parameters so that perfect tracking is 
asymptotically achieved. The adaptation law searches for parameters such 
that the response of the plant under adaptive control becomes the same as 
that of the reference model. The main objective of the adaptation is to make 
the control system stable and to make the tracking error converge to zero.   
Figure 3.18 illustrate the schematic structure of self-tuning approach for 
constructing adaptive controllers. In this approach the controller performs 
simultaneous identification of the plant. First, the parameters of the plant are 
estimated, and then the controller parameters are computed. 
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Figure 3.18: Self tuning control system. 
The design of adaptive controller is slightly different from the 
conventional one. In the conventional control, the controller structure is 
chosen first and then the parameters of the controller are computed using 
the known parameters of the plant, whereas in adaptive control being the 
plant parameters are unknown, the parameters of the controller are provided 
using the adaptation law. Briefly, the adaptive controller is usually designed 
using the following three steps:  
1. Choose a control law containing variable parameters. 
2. Choose an adaptation law for adjusting those parameters. 
3. Analyze the convergence properties of the overall control system. 
In this thesis we investigated adaptive strategies for hemodynamic 
variable control using one and more drugs.  
3.2.3.1.1 Model Reference Adaptive Control 
Figure 3.19 show the general structure of MRAC. The adaptive law of 
this controller has been presented by Sobel, Kaufman and Mabius (1982) 
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[88] and is defined by Equation (3.11), Equation (3.12), Equation (3.13), 
Equation (3.14), Equation (3.15), and  Equation (3.16). 
up = ky(t) × ym(t) + ku(t) × um(t) + ke(t) × [ym(t) − yp(t)] (3.11) 
where, up represent the control signal, ym is the outputs of reference model, 
um represent the set-point or desired value and yp is the plant outputs The 
controller’s parameters which represent by ky, ku and ke, these parameters 
being adaptive, see section 5.3 in chapter 5 for more details. The objective 
is to make the controlled output yp track the output of reference model ym. 
(ym(t) − yp(t)) = e(t) 
where, e(t) is the tracking error. 
up = kr(t) × r(t) (3.12) 
where,                                 r(t) = [
e(t)
ym(t)
um(t)
] 
and 
k(t) = [ke, ky, ku] (3.13) 
∴ 
kr(t) = kp(t) + k̂i(t) (3.14) 
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Figure 3.19: Block Diagram of General Structure of MRAC. 
The adaptive gain vector kr (t) in Equation (3.14) is obtained as a 
combination of proportional and integral gains as follows: 
kp(t) = e(t) × r
T × A (3.15) 
ki(t) = e(t) × r
T × B (3.16) 
In Chapter 5 we designed and implemented a multivariable MRAC in 
order to maintain the hemodynamic variables MAP and cardiac output (CO). 
3.2.3.1.2 Multiple Model Adaptive Control 
The control of dynamic systems with large uncertainties has received 
great attention by both control theorists and engineers. It is known that the 
system with unknown time invariant or slowly time varying parameters can 
get good performance by using conventional adaptive controller. But when 
the system boundary conditions change, the subsystem fails or a large 
external disturbance occurs, the system parameters will change immediately 
and the presence of the large parameter errors will generally result in a slow 
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reaction, slow convergence, poor transient response and even instability 
[89]. In order to solve this problem, an MMAC system has been implemented 
by Narendra and Balakrishnan in 1997 and 1994. The multiple models have 
been incorporated to improve the transient response as well as efficiency of 
the system [90] and [91]. 
3.2.3.1.3 Self-Tuning Control 
Self-tuning or self-adapting systems of automatic control are systems 
whereby adaptation to randomly changing conditions is performed by means 
of automatically changing parameters or via automatically determining their 
optimum configuration. In any non-self-tuning automatic control system there 
are parameters which have an influence on system stability and control 
quality and which can be tuned. If these parameters remain constant whilst 
operating conditions (such as input signals or different characteristics of 
controlled objects) are substantially varying, control can degrade or even 
become unstable. Manual tuning is often unwieldy and sometimes 
impossible. In such cases, not only is using self-tuning systems technically 
and economically worthwhile, but it could be the only means of robust 
control. Self-tuning systems can be with or without parameter determination 
[92]. 
3.2.4 Fuzzy Control 
Fuzzy controllers are very simple conceptually. They consist of an 
input stage, a processing stage, and an output stage, the consisting of these 
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stages has shown in Figure 3.20. The input stage maps sensor or other 
inputs, such as switches, thumb-wheels, and so on, to the appropriate 
membership functions and truth values. The processing stage invokes each 
appropriate rule and generates a result for each, then combines the results 
of the rules. Finally, the output stage converts the combined result back into 
a specific control output value [93]. 
In addition, fuzzy logic system design is not based on the 
mathematical process model. Fuzzy controllers designed using fuzzy logic 
implement human reasoning that has been programmed into membership 
functions, fuzzy rules and rule interpretation. A fuzzy logic controller involves 
four main stages: fuzzification, rule base, inference mechanism and 
defuzzification as shown in Figure 3.21. 
CONTROL UNIT
INPUT FUZZIFICATION OUTPUTDEFUZZIFICATION
INPUT STAGE PROCESSING OUTPUT STAGE
 
Figure 3.20: Block Diagram of General Structure for Fuzzy Control. 
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Figure 3.21: General structure of a fuzzy controller. 
The fuzzification and the defuzzification stages are needed to convert 
and reconvert real world crisp signals into fuzzy values and vice versa. The 
inference mechanism determines the matching degree of the current fuzzy 
input with respect to each rule and decides which rules are to be fired 
according to the input field. Next, the fired rules are combined to form the 
control actions [94]. 
3.2.5 Neural Network 
In this section we will present the general definition of a Neural 
Network. A Neural network is an interconnected system of simple elements 
called units or nodes. The elements functionality is based on the biological 
neuron. A biological neuron consists mainly of three parts: dendrites, soma, 
and axon as illustrated in Figure 3.22. The human brain comprises an 
estimated 100 billion neurons. The human nervous system can be divided 
into three stages as represented in block diagram in Figure 3.23. 
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Figure 3.22: Schematic of Biological Neuron. 
Neural
Network
Brain
Receptors EffectorsStimulus Response
 
Figure 3.23: The Stages of Nervous System. 
The inter unit connection strengths or weights used to store the 
processing ability of the network, are obtained by the process of adaptation 
to or learning from a set of training types [95]. 
The Artificial Neural Network (ANN) has been widely used in many 
fields such as process control, diagnostics, sensory prediction, identification, 
character recognition, robot vision, and forecasting, due to its ability to 
capture complex patterns present in the data. The ANN is an Information 
processing model that is inspired by the biological nervous systems, such as 
the brain which process information. ANNs, like humans, learn by example 
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via training. An ANN is configured to work for a particular application, such 
as pattern recognition or classification of data, through a process of learning. 
The ANN is learns as in biological systems which involve adjustments to the 
synaptic connections that exist between the neurones [96]. 
The neural network is composed of a number of node elements, which 
are connected together to produce either a single layer or multiple layers. 
These node elements are utilized in neural networks depending on the type 
of network considered. One commonly encountered model is a form of the 
McCulloch-Pitts neuron, as shown in Figure 3.24. 
Sum (s)
W11
W12
W13
W1n
X1
X2
X3
Xn
Bias (b)
f 1j jW X yj
 
Figure 3.24: Block Diagram of McCulloch-Pitts Neuron. 
Mathematically, the input signal Xi is multiplied by a weight parameter 
Wij and all weighted input signals are added to give the total input to the 
neuron as defined by Equation (3.18) and the output as defined by 
Equation (3.20). The bias b is a special weight which can be treated as a 
weight whose input is always equal to 1. 
s = W11x1 + W12x2 + W13x3 + ⋯+ W1nxn (3.17) 
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s = ∑Winxn
n
i=1
 (3.18) 
yj = f(w11x1 + w12x2 + w13x3 + ⋯+ w1nxn + b) (3.19) 
yj = f(∑Wijxj
n
i=1
) (3.20) 
The performance of the trained network depends on the learning 
algorithm, the number of layers, neurons, connections and on the type of 
transfer functions computed by each neuron. To avoid over and under fitting 
of the data the bias variance should be balanced by matching the complexity 
of the network to the complexity of the data. The transfer functions which 
commonly used are hard-limit, log-sigmoid and linear transfer functions, 
these have presented in Table 3-3. 
3.2.5.1 Advantages 
 A neural network is able to perform tasks that a linear program cannot. 
 Because of its parallel structure, a neural network can still function even 
when one of its elements fails. 
 A neural network is able to work by learning and does not need to be 
reprogrammed. 
 There are various neural network algorithms which cover a wide range of 
applications. 
 
 
CHAPTER 3. – CONTROL SYSTEM AND TOOLS  
 
61 
 
 
3.2.5.2 Disadvantages 
 A neural network requires training to operate. 
 A neural network needs to be emulated because its architecture is 
different from the architecture of microprocessors. 
 High processing time for large neural networks. 
Table 3-3: Types of Transfer Function. 
TRANSFER FUNCTION FIGURE 
Hard Limit transfer function: 
0  if   1
0 if   0


sy
sy
 
 
Symmetrical (Hard Limit) transfer function: 
0 if   1
0 if   1


sy
sy
 
 
Log-Sigmoid transfer function 
This transfer function takes the input and produces an output in 
the range 0 to 1, according to the expression: 
se
y


1
1
  
 
Linear transfer function: 
s=y  
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3.2.5.3 Training Neural Network 
Among the existing tuning techniques, the well-known Ziegler-Nichols 
tuning method can be implemented to tune the parameters of PID controller. 
This kind of method is simple and gives fixed values of the parameters. A 
controller with fixed parameters is not capable of responding to variations in 
system dynamics and changes in operating conditions. In blood pressure 
control, patients have different sensitivities and responses to drugs. We need 
a controller that is able to perform well for all types of patients.  
This chapter investigates the use of neural networks in adaptive 
control systems. Adaptive control solves the problem of the sensitivity to 
variation in the plant parameters. In the case of neural adaptive control, the 
controller parameters are changed by a neural network trained off-line. The 
training patterns are obtained using any design method of the controller for 
many different values of the plant parameters. A useful tool to train any 
neural adaptive controller has been developed. In this chapter we have 
investigated how to find the optimal way to make the PID controller able to 
control the multiple-drug delivery system online to regulate MAP and CO by 
administering two drugs. The Matlab Neural Network Fitting Tool (NNFT) tool 
was used to train the network [97] to make the PID controller adaptive. A 
neural network can be trained to perform a particular function by adjusting 
the values of the connections (weights) between elements. The neural 
network structure and training will be presented in chapter six. 
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3.3 Algorithm Optimisation 
A non-linear system is one of the reasons for the complexity of the 
tuning process of algorithm. Commonly, one can obtain controller settings 
with the traditional linear analysis methods and then utilizes the settings by 
implementing trial and error methods during a mission. Employing GAs 
methods gives the best values of the system parameters. Matlab Simulink 
Response Optimization Tools (SROT) [48] was used in this thesis to obtain 
optimal parameters values of the controllers. 
3.3.1 Genetic Algorithms 
Genetic Algorithms (GAs) are adaptive heuristic search algorithm 
based on the evolutionary ideas of natural selection and genetic. In different 
fields such as business, engineering, and science, these methods have been 
applied successfully to obtain suitable solutions for problems [98]. These 
methods are generally able to find optimal solution of the problems in 
suitable amounts of time. 
Genetic algorithms are part of development computing, which is a 
quickly growing area of artificial intelligence. GAs is a stochastic universal 
search method which mimics the process of natural evolution. It has been 
classified as one of the methods used for optimization. It is adapted from 
Darwin's theory of evolution. The algorithm starts with a set of hypothetical 
solutions and represented by chromosomes, called population. The solutions 
which obtained from one population are taken and used to structure a new 
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population. This is motivated by a hope, that the new population which has 
been considered is better than the previous one. The solutions which are 
selected are considered as new solutions (offspring) and chosen according 
to their fitness. The more suitable solutions have more chances to reproduce 
[99]. In order to produce offspring, the process starts with a set of randomly 
generated solutions then pairs of them recombined at random to produce 
offspring. The next generation is produced by keeping the best offspring and 
parents. 
Ordinarily, the population is initialized with N random strings 
(Chromosomes). The randomly generated initial population is represented by 
p(1). If p(t) represents the population at time t then the new population will be 
p(t+1) and it is created by applying a set of genetic operation as 
reproduction. There is a fitness value for each chromosome in a new 
population. As the chromosome has some parameters then the fitness value 
may be constricted from some parameters in each chromosome. The 
general genetic algorithm has the following structure [100, 101]:  
 Selection  
 Crossover  
 Mutation 
3.3.1.1 Selection 
The Selection is a genetic operator which selects the chromosome 
from the current generation’s population for inclusion in the next generation’s 
population. Before inserting the chromosome in the next generation’s 
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population, the chromosomes which have been selected may undergo 
crossover and/or mutation that depend on the probability of crossover and 
mutation. In this case the offspring chromosomes are actually the ones that 
have been inserted into the next generation’s population. 
3.3.1.2 Crossover 
Producing a new chromosome (offspring) needs to combine (mate) 
two chromosomes (parents) and this process is accomplished by the genetic 
operator called crossover. The idea behind crossover is that the new 
chromosome may be better than both of the parents if it takes the best 
characteristics from each of the parents. Crossover occurs during evolution 
according to a user-definable crossover probability. 
3.3.1.3 Mutation 
The modification of one or more gene values in a chromosome from 
its initial state is done by mutation, which results in a completely new gene 
values being added to the gene pool. With these new gene values, the 
genetic algorithm may be able to arrive at a better solution than was 
previously possible. This part is an important part of the genetic search. It is 
helpful to stop the population from stagnating at any local optima. Mutation 
happens during evolution according to a user-definable mutation probability. 
This probability should usually be set fairly low (0.01 is a good first choice). If 
it is set too high, the search will turn into a primitive random search. 
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3.3.1.4 Working principles of GAs 
Initialization: The implementation of any genetic algorithm starts by 
generating an initial population.  In many cases the initial population is 
generated randomly. 
Selection: Selection operator is applied to the current population to 
create an intermediate one. In the first generation, the initial population will 
consider as the intermediate one, while in the next generations this 
population is created by the application of the selection operator. 
Generation (Crossover–Mutation): In order to create the next 
generation, crossover and mutation operators are applied to the intermediate 
population to create the next population. Crossover is a reproduction 
operator, which forms a new chromosome by combining parts of each of the 
two parental chromosomes. Mutation is a reproduction operator that forms a 
new chromosome by making (usually small) alterations to the values of 
genes in a copy of a single parent chromosome. The process of going from 
the current population to the next population constitutes one generation in 
the evolution process of a genetic algorithm. If the termination criteria are 
satisfied the procedure stops, otherwise, it returns to the measure fitness 
step, as shown in Figure 3.25. 
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Figure 3.25: Flowchart of Genetic Algorithm. 
3.3.1.5 Main advantages:  
 GA can be used to solve any optimisation problem described with the 
chromosome encoding. 
 It is able to solve any problems with multiple solutions. 
 The technique can be used to solve problems that are non-parametric, 
non-continuous, non- differential, and even multi-dimensional in nature. 
 GA is very easy to understand and does not require a mathematical 
model. 
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3.3.1.6 Main disadvantages:  
 The GA approach uses extensive computational resources 
 There are problems that cannot be solved by GA. This is due to poorly 
known fitness functions which generate bad chromosome blocks. 
 With GA, there is no guarantee that the answer converges to global 
optimum. 
 The gap between optimisation response time is longer than the 
conventional gradient method. This limits its use in real-time applications. 
 In addition, the genetic algorithm applications which are used in real time 
controls are limited because of random solutions and convergence. 
 
 
 
CHAPTER 4. – CONTROL SCHEMES FOR SINGLE-INPUT SINGLE-OUTPUT (SISO) PATIENT 
RESPONSE MODEL 
 
69 
 
 
Chapter 4.  
CONTROL SCHEMES FOR SINGLE-INPUT SINGLE-OUTPUT (SISO) 
PATIENT RESPONSE MODEL 
4.1 Introduction 
Postoperative hypertension is a well-known complication of cardiac 
surgery in patients. The operation has been done at the Milton S. Hershey 
Medical Centre for 25 patients who have coarctation of the aorta. The report 
revealed a 56% incidence of paradoxical hypertension in the first time of 
postoperative period. The sympathetic nervous system is responsible for up- 
and down-regulating many homeostatic mechanisms. One of the 
sympathetic nervous system responsibilities is the initial phase of the 
paradoxical hypertension after surgery. In fact, many studies have tried to 
find out the reasons of the increase in the blood pressure in postoperative 
patients [1, 2]. 
SNP is a powerful anti-hypertension medicine. The action of sodium 
nitroprusside is one of direct dilatation of the vasculature, and it acts 
predominately on the tonic smooth muscle of the blood vessels. It must be 
given intravenously with careful manipulation of the infusion rate to avoid 
toxic SNP effects [3, 4]. The infusion of SNP and its effect on biological 
system presents a real problem in postoperative patients [6-9]. The 
automatic control of blood pressure in postoperative patients is desirable for 
 
CHAPTER 4. – CONTROL SCHEMES FOR SINGLE-INPUT SINGLE-OUTPUT (SISO) PATIENT 
RESPONSE MODEL 
 
70 
 
 
effective patient’s care and to avoid drug overdose [7]. There are large 
variations in the types of patient’s response to drugs. These models have 
been used to design several controllers [8, 9]. Slate et al., have determined 
the performance criteria of automatic control of blood pressure using the 
SNP drug [7, 42]. 
In this chapter, we propose to use two types of control strategies; an 
IMC and a PID controller. The aim is to compare the optimal performance of 
these two approaches. We used the GAs searching method as one of the 
SROT methods [48]. GAs is used to optimise the tuning parameters of the 
IMC and PID controllers [50]. Design and analysis for time-varying control 
systems are difficult and very often complex algorithms would be necessary 
for estimating the system parameters and for on-line tuning of the controller. 
An accurate estimation of the system parameters, especially time-delays, is 
the key for system stability and performance [50]. The IMC can be tuned to 
minimise the disturbance using only one tuning parameter, this parameter is 
K as shown in [8]. The PID controller can be tuned using three parameters, 
Kp, Ki and Kd. Optimal tuning of controller’s parameters are used to achieve 
optimal drug infusion rate. 
Researchers have conducted many studies on modelling and/or 
control of abnormal blood pressure in patients. This chapter presents a 
comparison of performances between IMC and PID controllers. The 
parameters of these controllers have been optimised by using GAs 
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optimization technique. The resulting controllers are tested on different 
models of patient’s sensitivity to SNP. 
4.2 SISO Patient Response Model 
Slate et al. [26, 42] have performed extensive research on patients to 
obtain the suitable model which can present the change in MAP to the 
infusion rate of drug. The model of patients’ response to the SNP is 
described by Equation (4.1). This is a linear first-order transfer function, 
obtained using correlation analysis with a pseudo-random binary signal 
(PRBS). 
Gp(s) =
∆P(s)
I(s)
=
Ke−Tis(1 + αe−Tcs)
τs + 1
 (4.1) 
where, the ΔP(s)  refers to the change in blood pressure in units of (mmHg), 
and the I(s) is the drug infusion rate measured in units of (ml/h), K is the 
patient’s sensitivity to the drug in units of (mmHg/ml/h), K(1+α) is the steady-
state gain or dose response, α is the fraction of re-circulation constant,   
represents the system time constant in units of (s), Ti is the initial transport 
delay in units of (s), and Tc is the re-circulation time delay in units of (s). 
MATLAB SIMULINK© tool box was used [102, 103] to simulate the 
model in Equation (4.1), as shown in Figure 4.1. 
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Figure 4.1: Block Diagram of Simulink Model of Patient Response. 
During clinical evaluations of the patient model, it was observed that 
several disturbances could have an effect on the patient’s behaviour, which 
could lead to an increase/decrease in the patient’s blood pressure. Slate et 
al. modelled the disturbance [7] as shown in Figure 4.2. 
RAS
Transfer Function
Input Output
12
30 s+ 1
-1.4
240 s+ 1
15
White Noise
Constant
Transport
Delay
Saturation
 
Figure 4.2: Block Diagram of Simulink Models of Disturbances. 
The random fluctuations and patient’s reflex response due to the drop 
in blood pressure are the main source of disturbance [7]. The disturbance is 
made up of two components: 
 Disturbances due to stochastic activity and respiration effects. 
 The patient’s reflex response due to a drop in the blood pressure. 
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The proposed controllers have been designed to achieve the required 
performance for different types of patients as given by the parameter 
variation shown in Table 4-1. The validation of the performance of the 
controllers is checked following two steps. In the first step the controllers are 
applied to three different types of patients, a nominal, sensitive and 
insensitive patient to the drug without disturbances. These will show that the 
controllers can meet the performance specification for which it was designed. 
In the second step the controllers have been applied to three different types 
of patients under the influence of disturbances that can have a nonlinear 
character as proposed by Slate et al. (1982) [7]. 
Table 4-1: The Patient’s Model Parameters Values. 
Parameters Unites Sensitive Nominal Insensitive 
Steady-state gain - K(1+α) mmHg/(ml/h) - 9 - 0.714 - 0.178 
Initial transport delay - Ti s 20 30 60 
Re-circulation time - Tc s 30 45 75 
Re-circulation - α - 0 0.4 0.4 
System time constant - τ s 30 40 60 
4.3 Controllers Optimization and Results 
A drug infusion controller should be designed to work well in a real-
time environment for a wide range of patients. The proposed controller 
structure should be as simple as possible to solve the drug infusion problem. 
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The following performance criteria introduced in [7] were used to 
evaluate the performance of our controllers: 
 Setpoint is -30 mmHg. 
 Settling time should be less than 1200 s. 
 Overshoot between 8 to 10 mmHg. 
 No steady-state offset but with an error tolerance of 5 mmHg. 
4.3.1 IMC Controller 
The structure of the IMC system consists of three terms as shown in 
Figure 2.1 in chapter two. The first term is the internal model which can be 
used to predict the process outputs. The second term is the internal model 
loop which uses the difference between the process output and the internal 
model output. Finally, the third term is the controller which uses the error to 
compute the future values of the process outputs. 
The difference between the output of the internal model and the 
process output is fed back to produce the error, e, used by the controller. 
This helps to reduce the effect of disturbances on the system [86]. 
We implemented the IMC which was first developed by Garcia et al. 
[46] on the patient model proposed by Slate et al. [26, 42]. The IMC has 
been applied to control blood pressure in [47, 49]. In [8] the analysis of the 
model parameters has shown that the model gain K, (see Figure 4.3 below) 
is the only parameter which affects the stability of the control system. 
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Figure 4.3: Full Control System with (GAs) Optimisation Technique. 
In this chapter we used the GAs optimisation search technique as one 
of the SROT methods to find the optimal value of the parameter “K” that 
satisfies the performance criteria and achieves the desired level of MAP (-30 
and -25 mmHg) with optimal values of infusion rate, with and without 
disturbance as shown in Table 4-2, Table 4-3, Table 4-4 and Table 4-5 
respectively. 
Table 4-2: IMC’s Gain with Disturbance and Setpoint is -30 mmHg. 
Patient’s Type Parameter “K” SNP (ml/h) MAP (mmHg) 
Sensitive - 4.5437 7.996 -30.30 
Nominal - 0.5746 72.08 -30.22 
Insensitive - 0.2792 289.3 -30.14 
 
Table 4-3: IMC’s Gain without Disturbance and Setpoint is -30 mmHg. 
Patient’s Type Parameter “K” SNP (ml/h) MAP (mmHg) 
Sensitive - 5.5985 3.333 -30 
Nominal - 1.8001 30.01 -30 
Insensitive - 0.4568 120.4 -30 
The system has been tested on different patient’s model in presence 
of disturbances with three types of sensitivities to drugs (sensitive, nominal 
and insensitive patients) with desired level of blood pressure as -30 mmHg. 
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Table 4-2 and Table 4-3  illustrate the disturbances effects on 
patient’s blood pressure, due to that the infusion rates of the drugs increases 
and decreases depending on the desired level of blood pressure. Figure 4.4, 
Figure 4.6 and Figure 4.8, demonstrate the simulation results for sensitive, 
nominal and insensitive patient’s responses to SNP, respectively. And 
Figure 4.5, Figure 4.7 and Figure 4.9 show the infusion rates for each 
patient. From these simulation results we have observed that the initial value 
of infusion rates is different from patient to patient. If the patient is sensitive 
the initial infusion rate is smaller compared to nominal and insensitive 
patients as shown in Figure 4.5 which has a value 2.641 ml/h, in Figure 4.9 
the initial value of infusion rate for insensitive patient is 42.98 ml/h. The effect 
of disturbances on the sensitive patient’s response and infusion rate has 
shown in Figure 4.10 and Figure 4.11. 
Table 4-4: IMC’s Gain with Disturbance and Setpoint is -25 mmHg. 
Patient’s Type Parameter “K” SNP (ml/h) MAP (mmHg) 
Sensitive - 4.5437 7.439 - 25.3 
Nominal - 0.5746 67.07 - 25.21 
Insensitive - 0.2792 269.2 - 25.14 
 
Table 4-5: IMC’s Gain without Disturbance and Setpoint is -25 mmHg. 
Patient’s Type Parameter “K” SNP (ml/h) MAP (mmHg) 
Sensitive - 5.5985 2.778 - 25 
Nominal - 1.8001 25.01 - 25 
Insensitive - 0.4568 100.3 - 25 
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Figure 4.4: Sensitive Patient's Response using IMC. 
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Figure 4.5: Sensitive patient’s infusion rate using IMC. 
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Figure 4.6: Nominal patient's response using IMC. 
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Figure 4.7: Nominal Patient's Infusion Rate using IMC. 
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Figure 4.8: Insensitive Patient's Response using IMC. 
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Figure 4.9: Insensitive Patient's Infusion Rate using IMC. 
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Figure 4.10: Sensitive Patient Response with and without Disturbances using IMC. 
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Figure 4.11: Sensitive Patient Infusion Rate with and without Disturbances using IMC. 
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4.3.2 PID Controllers 
The three-term controller, PID, shown in Figure 4.12, has been widely 
used in the field of process control because of its simplicity and robustness. 
In conventional PID control, once the well-tuned PID gains are obtained, the 
controller usually exhibits good performance. However, when the dynamic 
characteristics of the system are time dependent or the operating conditions 
of the system vary, it is necessary to retune the PID parameters again. The 
manual tuning of PID controllers, which requires optimization of the 
parameters, is a time-consuming task. To deal with this difficulty, much effort 
has been invested in developing systematic tuning methods. Many of these 
methods depend on knowledge of the plant model. Some of these tuning 
methods are described in [83, 84]. 
 
Figure 4.12: Block Diagram of PID Controller with (GAs) Optimisation Technique. 
In this part, the GAs optimisation technique as one of the SROT 
methods has been implemented to obtain the optimal values of PID controller 
1
s
du /dt
kp ki
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+
+
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parameters, Kp, Ki, and Kd. The optimisation results achieved satisfy the 
performance criteria and achieve the desired level of MAP (-30 and -25 
mmHg) with optimal values of infusion rate, with and without disturbance as 
shown in Table 4-6, Table 4-7, Table 4-8 and Table 4-9 respectively. 
Table 4-6: PID Controller’s Gain with Disturbances and Setpoint -30 mmHg. 
Patient’s type 
Controller’s Parameters SNP 
(ml/h) 
MAP 
(mmHg) Kp Ki Kd 
Sensitive - 0.0898 0.0291 0.4592 7.984 - 30.38 
Nominal - 0.3167 0.0347 0.4919 72.12 - 30.19 
Insensitive - 1.1939 0.0244 1.714 289.1 - 30.15 
 
Table 4-7: PID Controller’s Gain without Disturbances and Setpoint -30 mmHg. 
Patient’s type 
Controller’s Parameters SNP 
(ml/h) 
MAP 
(mmHg) Kp Ki Kd 
Sensitive 0.001 - 0.6084 1.1129 3.333 - 30 
Nominal - 0.3188 0.0151 -0.174 30.01 - 30 
Insensitive - 0.1852 0.0594 - 0.1992 120.4 - 30 
The system has been tested using PID controller with and without 
disturbances and with different types of patient’s sensitivities to SNP in order 
to decreases MAP by 30 mmHg. The simulation results of the patient’s 
responses to the drug and the drug infusion rates are presented in Table 4-6 
and Table 4-7. From these results we have observed that the drug infusion 
rates are more than 40% smaller in the absence of disturbances. 
Figure 4.13, Figure 4.15 and Figure 4.17, show the simulation 
results of the system for sensitive, nominal and insensitive patient’s 
responses to SNP, respectively. Figure 4.14, Figure 4.16 and Figure 4.18 
 
CHAPTER 4. – CONTROL SCHEMES FOR SINGLE-INPUT SINGLE-OUTPUT (SISO) PATIENT 
RESPONSE MODEL 
 
83 
 
 
display the infusion rates of SNP for each patient from these results we have 
observed that the initial infusion rate is different from patient to patient. The 
quantities of the initial drug’s infusion rate are 2.694 ml/h for sensitive 
patient, 9.501 ml/h for nominal patient and 35.82 ml/h for insensitive patient. 
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Figure 4.13: Sensitive patient's response using PID. 
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Figure 4.14: Sensitive Patient’s Infusion Rate using PID. 
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Figure 4.15: Nominal Patient's Response using PID. 
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Figure 4.16: Nominal Patient’s Infusion Rate using PID. 
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Figure 4.17: Insensitive Patient's Response using PID. 
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Figure 4.18: Insensitive Patient’s Infusion Rate using PID. 
Table 4-8: PID Controller’s Gain with Disturbances and Setpoint -25 mmHg. 
Patient’s type 
Parameters 
SNP (ml/h) MAP (mmHg) 
Kp Ki Kd 
Sensitive - 0.0898 0.0291 0.4592 7.427 - 25.38 
Nominal - 0.3167 0.0347 0.4919 67.11 - 25.18 
Insensitive - 1.1939 0.0244 1.714 269 - 25.14 
 
Table 4-9: PID Controller’s Gain without Disturbances and Setpoint -25 mmHg. 
Patient’s type 
Parameters 
SNP 
(ml/h) 
MAP 
(mmHg) 
Kp Ki Kd 
Sensitive 0.001 - 0.6084 1.1129 2.778 - 25 
Nominal - 0.3188 0.0151 - 0.174 25.01 - 25 
Insensitive - 0.1852 0.0594 - 0.1992 100.3 - 25 
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Table 4-8 and Table 4-9 illustrate the effect of the disturbances on the 
values of drug infusion rates when the desired level of MAP is -25 mmHg. 
For example the infusion rate for sensitive patient in the presence of 
disturbances is 7.427 ml/h and without disturbances is 2.778 ml/h. 
Figure 4.19 and Figure 4.20 below shows the simulation results for 
sensitive patient response and the infusion rates of SNP when the desired 
level of MAP is -25 mmHg. From Figure 4.20 we have observed that the 
initial infusion rate in with disturbances is 2.245 ml/h but without disturbances 
the initial infusion rate is zero. 
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Figure 4.19: Sensitive Patient Response with and without Disturbances using PID. 
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Figure 4.20: Sensitive Patient Infusion Rate with and without Disturbances using PID. 
4.4 Comparison of Results 
Both the IMC and the PID controllers were simulated using 
Matlab/Simulink and tested on three types of patient’s model, the nominal, 
the sensitive and the insensitive. The optimal parameters of the controllers 
have been obtained using GAs optimisation. The patient’s responses to the 
SNP drug were obtained in the presence of disturbances. The patient’s 
model parameters are shown in Table 4-1. 
Figure 4.21, Figure 4.22, Figure 4.23 and Figure 4.24 shows the 
simulation results of the nominal, sensitive and insensitive patient’s 
responses to a step decrease of -30 mmHg in the SNP drug infusion rate 
with the PID and IMC controller respectively. 
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Table 4-10, Table 4-11 and Table 4-12 have displayed the time it 
takes the responses to reach -30 mmHg (settling time), (overshoot) and 
(Undershoot) for both controllers. 
Table 4-10: Performances of the Controllers for Sensitive Patient Model. 
Parameters PID IMC 
Setting Time (s) 697 939 
Overshoot (mmHg) 0 0 
Undershoot (mmHg) 0.498 0.597 
 
Table 4-11: Performances of the Controllers for Nominal Patient Model. 
Parameters PID IMC 
Setting Time (s) 1007 709 
Overshoot (mmHg) 0 0 
Undershoot (mmHg) 0.597 0.597 
 
Table 4-12: Performance of the Controllers for Insensitive Patient Model. 
Parameters PID IMC 
Setting Time (s) 1123 1123 
Overshoot (mmHg) 0 0 
Undershoot (mmHg) 0.597 0.597 
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Figure 4.21: Patient's responses using PID. 
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
50
100
150
200
250
300
Time (sec)
In
fu
si
o
n
 R
a
te
 (
m
l/
h
)
 
 
Infusion rate of SNP for sensitive patient
Infusion rate of SNP for nominal patient
Infusion rate of SNP for insensitive patient
 
Figure 4.22: Infusion Rates of SNP for Patients using PID. 
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Figure 4.23: Patient's Responses using IMC. 
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Figure 4.24: Infusion Rates of SNP for Patients using IMC. 
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These results demonstrate that the performance criteria are satisfied 
with both the PID controller and IMC controller. However, the settling time for 
the PID controller for sensitive patient’s responses is shorter than with the 
IMC controller, the difference in settling time is around 242 s. The overshoot 
is zero with both controllers for the three types of patient. The IMC controller 
has achieved a shorter settling time than PID controller in nominal patient 
and the settling time is the same in insensitive patient. Both controllers have 
undershoot with little change, in sensitive patient. In nominal and insensitive 
types of patient the PID controller has a smaller value of undershoot. Also, in 
nominal and insensitive types of patient, both controllers have the same 
value of undershoot. 
Figure 4.25, Figure 4.26 and Figure 4.27 depicts the performance of 
the PID and IMC control. Both have achieved the performance criteria which 
were specified in section 4.3. From Figure 4.28, Figure 4.29 and Figure 
4.30 we observed that for the sensitive, nominal and insensitive patient the 
infusion rate of SNP achieved with PID control is more or less the same as 
with IMC as presented in Table 4-13 and Table 4-14. The maximum value of 
the infusion rate does not exceed 300 ml/h even for the “insensitive patient” 
as reported by Auer and Rodler [44]. As expected, the infusion rate for the 
sensitive patient is low, around 8 (ml/h), since this patient’s model has zero 
recirculation factors. In nominal and insensitive patients, the PID controller 
has a smaller initial infusion rate than IMC controller. 
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Figure 4.25: Sensitive Patient Response using PID and IMC. 
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Figure 4.26: Nominal Patient Response using PID and IMC. 
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Figure 4.27: Insensitive Patient Response using PID and IMC. 
Table 4-13: SNP Infusion Rates for Patients using PID. 
Patient’s type Final infusion rate (ml/h) Initial infusion rate (ml/h) 
Sensitive 7.984 2.694 
Nominal 72.12 9.501 
Insensitive 289.1 35.82 
 
Table 4-14: SNP Infusion Rates for Patients using IMC Controller. 
Patient’s type Final infusion rate (ml/h) Initial infusion rate (ml/h) 
Sensitive 7.994 2.641 
Nominal 72.08 20.88 
Insensitive 289.3 42.98 
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Figure 4.28: SNP's Infusion Rate for Sensitive Patient using PID and IMC. 
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Figure 4.29: SNP's Infusion Rate for Nominal Patient using PID and IMC. 
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Figure 4.30: SNP's Infusion Rate for Insensitive Patient using PID and IMC. 
4.5 Summary 
The abnormal blood pressure is one of the most common 
complications which have been observed in postoperative patients. The 
infusion of the drugs is used to maintain the blood pressure at the desired 
level and its effect on the biological system presents a real problem in 
postoperative patients. The implementation of automatic control drug delivery 
system has the potential to improve patient care and reduce human error. 
This chapter has presented a comparison of performance between IMC and 
PID control of MAP for a single drug. The parameters of these controllers 
have been optimised using GAs optimisation technique. The resulting 
controllers are tested on different sensitivity types of patients’ response to 
SNP, for the desired MAP drop level. 
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In Chapter 5, the MRAC control system has been designed and 
implemented to regulate MAP and CO using two drugs, SNP and DPM. 
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Chapter 5.  
MRAC FOR MULTI-INPUT MULTI-OUTPUT (MIMO) PATIENT RESPONSE 
MODEL 
5.1 Introduction 
If blood pressure is controlled and oscillations in the hemodynamic 
variables are reduced, patients experience fewer complications after surgery. 
In clinical practice, this is usually achieved using manual drug delivery. Given 
that different patients have different sensitivity and reaction time to drugs, 
determining manually the right drug infusion rates may be difficult. This is a 
problem where automatic drug delivery can provide a solution, especially if it 
is designed to adapt to variations in the patient’s model. 
Various automatic control techniques have been used to control the 
hemodynamic variables. Many studies have focused on the infusion of a 
single drug to lower the patients’ blood pressure and maintain it at the 
desired level using in particular the vasoactive drug sodium nitroprusside 
SNP [7, 47, 49, 83, 103-106] and [25]. In chapter four we have covered the 
MAP regulation using single drug, implementing two types of controller, PID 
and IMC and the results have been published [107]. Slate and Sheppard in 
1982 have used a one-drug patient model and implemented a nonlinear 
digital PID controller to regulate MAP [7]. In 2005, Zheng and Zhu developed 
a MMAC based on FC [106]. In 1991, Behbehain and Cross proposed an 
integrating self-tuning control strategy to maintain MAP using SNP [108]. In a 
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recent study Zhu et al. in 2008 presented an adaptive control algorithm for 
updating time delays and sensitivity of the hemodynamic model [109]. 
Poterlowicz et al. in 2007 and 2008 developed an optimal IMC system to 
regulate MAP with the SNP drug [47, 49]. 
Blood pressure is commonly controlled using more than one drug. 
Several studies have investigated the automation of multiple drug-deliveries. 
Yu et al. in 1990 developed a computer model to simulate the hemodynamic 
variables responses to DPM and SNP in a failing heart [10]. They simulated 
the circulatory system with a nonlinear electrical analog model with 
baroreflex feedback. In 1999, Achuthan et al. used the computer model 
developed in 1990 by Yu et al. to test an indirect adaptive algorithm based 
on parameter identification and linear quadratic regulation [11]. An adaptive 
algorithm to control MAP and CO in anesthetized dogs with infusion of SNP 
and DPM has been implemented by Voss et al. in 1987 [12]. Yu et al. in 1992 
proposed an algorithm that utilized six model predictive controllers to 
regulate MAP and CO with SNP and DPM. They carried out tests on 
laboratory animals that were altered to exhibit symptoms of congestive heart 
failure [13]. Due to the variations in plant parameters and time delay 
elements. Ozecelik et al. in 1999 have developed and implemented the 
robust DMRAC to regulate MAP and CO using SNP and DPM [71]. Several 
experiments have been done on animal using multi-drug administration 
system,  Koivo et al. in 1978, 1980 and 1981 [14-16]., Stern et al. in 1981 
[17] and in 1984 by Kaufman et al. [18]. 
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In this chapter we have used a two-input, two-output patient model 
with matrix elements represented by first-order transfer functions with time 
delays to investigate the performance of a MRAC system. The controller 
parameters have been adapted using the diagonal (6×6) weighting matrices 
discussed in [63]. Matlab Simulink Toolbox was used to design and simulate 
the proposed control system. 
5.2 Patients’ Model Description 
The objective of the control system is to decrease the patient’s MAP 
and increase CO to the desired values by tracking the reference signals. In 
this chapter we have adapted the patients’ hemodynamic model which first 
introduced by Ozcelik et al. [71]. This model has been defined by the linear 
small-signal first-order transfer function matrix as given in Equation (5.1). 
The drugs used to control the variables CO and MAP are DPM and SNP. 
DPM increases both CO and MAP while SNP increases CO and decreases 
MAP. The drug infusion rates are measured in (µg/min.kg), CO is measured 
in (ml/min.kg) and MAP is measured in millimetres of mercury (mmHg). 
[
∆CO(s)
∆MAP(s)
] =
[
 
 
 
 
K11e
−T11s
τ11s + 1
K12e
−T12s
τ12s + 1
K21e
−T21s
τ21s + 1
K22e
−T22s
τ22s + 1 ]
 
 
 
 
[
∆DPM(s)
∆SNP(s)
] 
(5.1) 
where, the Kij is referring to the model gains. The Tij represent the time 
delays between inputs and the system responses measured in units of (s).
ij
 , 
represent the system time constants in units of (s). 
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During clinical evaluations of the patient model, it was observed that 
disturbances could have an effect on the patient’s hemodynamic states, 
which could lead to an increase or decrease in blood pressure [7]. Therefore 
Equation (5.1) was modified to include the disturbance terms D1 and D2 as 
shown in Equation (5.2) below, where D1 and D2 are the disturbances in CO 
and MAP. 
[
∆CO(s)
∆MAP(s)
] =
[
 
 
 
 
K11e
−T11s
τ11s + 1
K12e
−T12s
τ12s + 1
K21e
−T21s
τ21s + 1
K22e
−T22s
τ22s + 1 ]
 
 
 
 
[
∆DPM(s)
∆SNP(s)
] + [
D1
D2
] (5.2) 
and 
CO =
K11e
−T11s
τ11s + 1
× DPM +
K12e
−T12s
τ12s + 1
× SNP + D1 (5.3) 
MAP =
K21e
−T21s
τ21s + 1
× DPM +
K22e
−T22s
τ22s + 1
× SNP + D2 (5.4) 
The patient SIMULINK model has been built from Equations (5.3) 
and (5.4), and the SIMULINK block diagram of the hemodynamic model is 
shown in Figure 5.1. 
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Figure 5.1: Simulink Block Diagram of the Plant Model. 
The nominal values and range of the parameters in the patient model 
are given in Table 5-1. 
The desired response is represented by the reference model transfer 
function of CO and MAP as shown in Equation (5.5) [63]. 
H(s) =
ymi(s)
umi(s)
=
1
τis + 1
 (5.5) 
where, ym1 and ym2 are the outputs of the first and second reference model 
respectively. um1 and um2 are the inputs of the first and second reference 
model respectively, 
1
= 300 s. and 
2
= 90 s. are the time constants of the 
reference models chosen to produce the desired speed of hemodynamic 
response. The constraints on normalized drug dosage are selected as 
follows: 0 ≤ DPM ≤ 6 mg\min.kg and 0 ≤ SNP ≤ 10 mg\min.kg. 
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Table 5-1: Nominal Values and Range of the Parameters in the Patient Model. 
parameters Nominal Ranges Unit 
11K  5 1 to 12 ml/ g  
11  300 70 to 600 s 
11T  60 15 to 60 s 
12K  12 -15 to 25 ml/ g  
12  150 70 to 600 s 
12T  50 15 to 60 s 
21K  3 0 to 9  mmHg/ / min.g kg  
21  40 30 to 60 s 
21T  60 15 to 60 s 
22K  -15 -13 to -50  mmHg/ / min.g kg  
22  40 30 to 60 s 
22T  50 15 to 60 s 
5.3 Model Reference Adaptive Control System 
Figure 5.2 shows the diagram of the patient’s model and MRAC 
system. The MATLAB function block is used to obtain the reference signal um 
depending on the patient’s case. 
The control signal up(t) which represents the drug infusion rate is 
formulated as a linear combination of the error feedback [Ke(t) x e] and the 
two feed-forwards reference model output [Ky(t) x ym] and reference model 
input [Ku(t) x um]. The adaptive control law combines the values of the 
tracking error e, the reference model output ym and the reference model input 
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um with appropriate adaptive gains [Ky, Ku and Ke] [110]. The adaptive control 
law is given by: 
Up(t) = Ky(t) × ym(t) + Ku(t) × um(t) + Ke(t)[ym(t) − yp(t)] (5.6) 
Up(t) = Kr(t) × r(t) (5.7) 
Kr(t) = [Ke, Ky, Ku]  
∴  Kr(t) = Kp(t) + Ki⏞ (t) (5.8) 
r(t) = [
e(t)
ym(t)
um(t)
] (5.9) 
where, e(t) = ym(t) − yp(t) 
Patient
Patient
Monitor
Infusion
Device
+
+
+
Ke
Ky
Ku
Reference
Model
MATLAB
Function
Drug Infusion
Rates
e = ym - yp 
ym
yp
um
CONTROLLER
 
Figure 5.2: General form of the patient’s model with MRAC. 
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The adaptive gain vector Kr(t) in Equation (5.8) is obtained as a 
combination of integral and proportional gains as follows: 
Kp(t) = e(t) × r
T × A (5.10) 
Ki⏞ (t) = e(t) × r
T × B (5.11) 
where,  
A and B are nr by nr (6 x 6) time invariant weighting matrices. 
A =
[
 
 
 
 
 
A1 0 0
0 A2 0
0 0 A3
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
A4 0 0
0 A5 0
0 0 A6 ]
 
 
 
 
 
 B =
[
 
 
 
 
 
B1 0 0
0 B2 0
0 0 B3
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
B4 0 0
0 B5 0
0 0 B6 ]
 
 
 
 
 
 
 
As the system has two inputs and two outputs we have designed two 
controllers, the function of the first controller is to control the infusion rate of 
the first drug DPM and the second controller to control the infusion rate of the 
second drug SNP. Figure 5.3 depicts the Simulink block diagram of the 
system. The Up1 and Up2 represented the outputs of both controllers 
respectfully as shown in Equation (5.12) and Equation (5.13). 
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Figure 5.3: Simulink Block Diagram of the Patient Model with the MRAC. 
Up1 = [Kp1(t) + Ki1⏞ (t)] r(t) (5.12) 
Up2 = [Kp2(t) + Ki2⏞ (t)] r(t) (5.13) 
5.3.1 Control Objectives 
The performance of the MRAC is investigated by simulating two 
patients’ situations where both MAP and CO are outside the normal values of 
120 mmHg for MAP and 100 ml/min.kg for CO. The initial values of the 
patients’ MAP and CO are chosen as 140 mmHg and 80 ml/min.kg 
respectively. The control objective is to decrease MAP down to 120 mmHg 
and increase CO up to 100 ml/min.kg. 
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Table 5-2 below presents the values of diagonal matrix which have 
been obtained and used to adapt the controllers. 
Table 5-2: The Values of A and B Diagonal. 
A1 A2 A3 A4 A5 A6 
2x10
-06
 1.6x10
-04
 2.9x10
-06
 10
-07
 4.x10
-10
 10
-04
 
B1 B2 B3 B4 B5 B6 
10
-05
 2.8x10
-08
 1.1x10
-06
 10
-06
 10
-08
 10
-10
 
Many simulation trials were conducted to find the best values of the 
above matrices that give MAP and CO responses within specifications. The 
performance was obtained using the values shown above. 
5.4 Simulation Results 
The proposed algorithm has been implemented, and tested through a 
set of experiments by considering decreasing MAP by 20 mmHg and 
increasing CO by 20 ml/min.kg. 
Table 5-1 presents the lists of the nominal values and the range of the 
parameters of patient’s model which were simulated using Matlab/Simulink 
as shown in Figure 5.3. The simulations were done for different patient’s 
sensitivity. The MRAC has been implemented to compute the drugs infusion 
rates which are the inputs to the MIMO patient model. 
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Simulations were conducted for all the parameters values in the range 
to find by trial and error the best weighting matrices A and B. The 
proportional and integral gains were then calculated from Equation (5.10) 
and Equation (5.11) using these weighting matrices. 
In order to compare the performance of our MRAC with previous 
research work as in [63], the comparisons have been done without the 
presence of disturbances on the patient’s model. The simulations were also 
carried out with K22 in the range -15, -20, and -50 (𝑚𝑚𝐻𝑔/[𝜇𝑔 𝑚𝑖𝑛. 𝑘𝑔]⁄ ). 
These are shown in the following figures, Figure 5.4, Figure 5.5, Figure 5.6, 
Figure 5.7, Figure 5.8 and Figure 5.9 and data is presented in Table 5-3. 
Table 5-3: Comparisons between MRAC and Non-Adaptive PID. 
Hemodynamic 
Variables 
K22 
Performance 
Measures 
Results 
using 
MRAC 
Results 
using non-
adaptive PID 
Results of 
[63] using 
MRAC 
MAP 
-20 
Settling Time (s) 544 293 1320 
Overshoot (mmHg) zero zero 4 
-50 
Settling Time (s) 506 345 660 
Overshoot (mmHg) zero 0.71 1.75 
CO 
-20 
Settling Time (s) 1232 887 1440 
Overshoot 
(ml/min.kg) 
zero Zero Little 
-50 
Settling Time (s) 1822 1100 1380 
Overshoot 
(ml/min.kg) 
zero 1.73 Little 
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We observe that the overshoot of both MAP and CO is zero. However, 
in [63] the MAP overshoots by 20% when K22 = -20. The MRAC showed 
some improvements when K22 = -20. Figure 5.8 and Figure 5.9 shows the 
simulation results of patient model and reference model responses when K22 
= -50. In this case the simulation needs more than 7500 s to illustrate the full 
system response. From this we observed that in this patient’s case the 
system response needs more time to reach the desired level of MAP and CO 
as compared with other cases, also Figure 5.8 shows that system response 
of MAP has slight oscillation within 0.4 mmHg. The Figure 5.10 has displays 
these oscillations more clearly. 
Table 5-4: System Responses and Drugs Infusion Rates. 
Patient’s case (K22) 
“mmHg/[µg/min.kg] 
MAP 
“mmHg” 
CO 
“ml/min.kg” 
SNP 
“µg/min.kg” 
DPM 
“µg/min.kg” 
-15 -15 15 1.081 0.4053 
-20 -15 15 0.8824 0.8821 
-50 -15 15 0.419 1.986 
-15 -20 20 1.441 0.5405 
-20 -20 20 1.176 1.176 
-50 -20 20 0.5594 2.657 
 
Table 5-4 presents the simulation results of the system responses 
and the optimal infusion rates of SNP and DPM for different patient’s case 
with different desired level of MAP and CO. 
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Figure 5.4: Patient Model and Reference Model Responses without Disturbance, (MAP), K22=-15 
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Figure 5.5: Patient Model and Reference Model Responses without Disturbance, (CO), K22=-15. 
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Figure 5.6: Patient Model and Reference Model Responses without Disturbance, (MAP), K22=-20. 
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Figure 5.7: Patient Model and Reference Model Responses without Disturbance, (CO), K22=-20. 
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Figure 5.8: Patient Model and Reference Model Responses without Disturbance, (MAP), K22=-50. 
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Figure 5.9: Patient Model and Reference Model Responses without Disturbance, (CO),  K22=-50. 
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Figure 5.10: Slight Oscillation of Patient Response Model without Disturbances, (MAP), K22=-50. 
The MRAC performance was also investigated when both MAP and 
CO are subject to the effect of disturbances. We have employed white noise 
as part of the disturbance model with variance values that D1 and D2 of 
0.01, 0.02 and 0.03. The control objective is to maintain MAP and CO at -20 
and CO is 20. The results are presented in Table 5-5 and depicted in Figure 
5.11, Figure 5.12, Figure 5.13 and Figure 5.14.These results demonstrate 
that the controller copes well with disturbances in the hemodynamic 
responses. The changes in MAP and CO are very small and the infusion 
rates are well within the safe range. 
 
 
 
CHAPTER 5. – MRAC FOR MULTI-INPUT MULTI-OUTPUT (MIMO) PATIENT RESPONSE MODEL  
 
114 
 
 
Table 5-5: Simulation Results with and without Disturbances, K22 Equal -20. 
Without Disturbances With Disturbances 
MAP 
“mmHg” 
CO 
“ml/min.kg” 
SNP 
“µg/min.kg” 
DPM 
“µg/min.kg” 
D1&D2 
MAP 
“mmHg” 
CO 
“ml/min.kg” 
SNP 
“µg/min.kg” 
DPM 
“µg/min.kg” 
- 20 20 1.176 1.176 
0.001 - 20.16 19.85 1.168 1.186 
0.002 - 20.23 19.79 1.165 1.191 
0.003 - 20.28 19.75 1.162 1.194 
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Figure 5.11: Patient Model Responses without Disturbances, K22=-20. 
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Figure 5.12: Patient Model Responses with Disturbances 0.01, K22=-20. 
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Figure 5.13: : Patient Model Responses with Disturbances 0.02, K22=-20. 
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Figure 5.14: Patient Model Responses with Disturbances 0.03, K22=-20. 
5.5 Summary 
In this chapter we implemented a MIMO control system using two 
interacting drugs to control both MAP and CO of patients with different 
sensitivity. A multivariable MRAC algorithm is developed using a two-input, 
two-output patient model. The control objective is to maintain the 
hemodynamic variables MAP and CO at the normal values by 
simultaneously administering two drugs; SNP and DPM. Computer 
simulations were carried out to investigate the performance of this controller. 
The results show that the proposed adaptive scheme is robust with respect 
to disturbances and variations in model parameters. 
The proposed scheme was designed and evaluated by simulating 
variations in patient sensitivity and disturbances in CO and MAP. The 
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simulation results have confirmed that MRAC is potentially useful for 
regulating MAP and CO by computing the DPM and SNP infusion rates. The 
proposed algorithm demonstrated better performance as compared to a non-
adaptive PID controller. In these simulation studies the proposed scheme 
produced better performance compared to reported results, particularly for 
the updated controller’s gain K22 (mean arterial pressure gain). This includes 
shorter settling time and very small or no overshoot when the patient 
sensitivity K22 less than or equal -20. 
In Chapter 6 we will present an investigation into the design and 
development of a Neuro-PID control scheme for hemodynamic variables 
control using two drugs. 
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Chapter 6.  
ADAPTIVE MULTI-DRUG NEURO-PID CONTROL SCHEME FOR BLOOD 
PRESSURE CONTROL 
6.1 Introduction 
The adaptive controller based on the Generalized Fuzzy Neural 
Network (GFNN) has been applied to control MAP using SNP in 2003 by Er 
and Gao [111]. In 2006, Kashihara presented the implementation of a 
multiple adaptive predictive control based on neural networks to maintain the 
unanticipated responses to drugs of CO and MAP [75].  In 2000 Shu and Pi 
have used PID controller based on neural network to control time-delay 
systems, proposed a PID neural network which consists of three layers 
where the hidden layer's units are proportional, integral and derivative 
neurons and its weights are adjusted by the back-propagation algorithm 
[112].  
In this chapter we propose a novel Neuro-PID control scheme to 
regulate MAP and CO using SNP and DPM. The parameters of the PID 
controller are updated using MATLAB neural network fitting tool (NNFT). The 
controller parameters are adapted using four inputs and three outputs as 
patients’ sensitivities and controller parameters respectively. The proposed 
scheme has been implemented, tested and verified to demonstrate its merits 
and capabilities compared to existing approaches. 
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6.2 Neuro-PID Adaptive Control 
Three-term controller, PID has been widely used in the field of 
process control because of its simplicity and robustness. In conventional PID 
control, once the well tuned PID gains are obtained, the controller usually 
exhibits good performance. However, when the dynamic characteristics of 
the system are time dependent or the operating conditions of the system 
vary, it is necessary to retune the PID parameters again. This controller has 
been implemented on patient’s model which has been represented in chapter 
5 section 5.2 as shown in Figure 5.1 to regulate CO and MAP.  
 
Figure 6.1: General Form of the Patient’s Model with Neural PID Controller. 
The manual tuning of PID controllers is a time-consuming task. To 
deal with this difficulty, much effort has been invested in developing 
systematic tuning methods. Many of these methods depend on knowledge of 
the plant model. Some of these tuning methods are described by Åström  et 
al. in 1995 and 1993 [83, 84]. In this chapter we used Simulink Response to 
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obtain the optimal initial values of the controller parameters and the neural 
network is used to tune the PID controller for all types of patient’s 
sensitivities. Figure 6.1 above depicts the general form of the system. 
Since the patient model has two inputs and two outputs we designed 
two controllers, the first controller function aims to control the infusion rate of 
the first drug DPM, and the second controller function is to control the 
infusion rate of the second drug SNP. The parameters of both controllers are 
updated by the neural network. Figure 6.2 depicts the simulink block 
diagram of the system. This system has the following: 
 One patient model with two inputs and two outputs includes 
disturbances, the drugs infusion rates represent the inputs and the 
outputs are the patient’s responses to drugs. 
 Two PID controllers with three parameters for each one, the first 
controller is utilized to control the infusion rates of DPM, and the second 
one is used to control SNP infusion rates. 
 The training neural network model. This model has four inputs and six 
outputs, normalization inputs data model and de-normalisation outputs 
data model. 
 Two set-points, one represents the desired level of CO and the other 
represents the desired level of MAP. 
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Figure 6.2: Simulink Block Diagram of the Patient Model with PID Controllers and Neural 
Networks. 
6.2.1 Control Objective 
The performance of a Neuro-PID controller is investigated by 
simulating two hemodynamic variables; MAP and CO. In order to manage 
the hemodynamic variables, due to the complex, nonlinear behaviour of 
physiological systems, a good controller is difficult to design. We developed 
a Neuro-PID controller using NNFT to update the PID controller depending 
on patients’ cases. The data which have been used to train the Neural 
Network has been obtained from several experiments, to track a reference 
signal and to optimize the response with uncertainties in the patient’s model. 
The PID controller has been implemented as two SISO controllers with three-
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term, proportional, integral and derivative. These terms are represented as 
controller parameters, Kp, Ki, and Kd. The objectives of the proposed 
algorithm are: 
 Regulate two hemodynamic variables, MAP and CO by the automated 
infusion rates of inotropic and vasoactive drugs which have been used to 
decrease MAP and to increase CO, up to desired values. 
 Infused suitable amounts of SNP and DPM within in order to achieve the 
desired level of the hemodynamic variables with settling times and 
overshoot criteria which has been presented in chapter 4 section 4.3. 
With the participation of the neural network, PID controller can 
simulate online MAP and CO and obtain the optimal infusion rates of the 
drugs and cover wide range of patient’s cases. 
6.2.2 Control Parameters Optimisation 
In this section we employed the Response Optimisation (RO) from 
Simulink Design Optimisation Technique (SDOT) ot obtain the optimal values 
of PID parameters that Kp, Ki, and Kd. 
The simulink block diagram of the system shown in Figure 6.3 
includes the patient’s model, two PID controllers, two step points (CO 
reference signal. and MAP reference signal), and two signal constraints used 
to track the reference signals. Figure 6.4 depicts the structure of the PID 
controller. 
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Figure 6.3: Simulink Block Diagram of the Process of Optimisation. 
 
Figure 6.4: Simulink Block Diagram of PID Controller. 
 
The optimisation operation shows how to obtain the optimal values of 
PID parameters to meet the model output reference signal for CO and MAP. 
The steps of the optimisation’s operation are shown in the following Figures 
and we have considered case number 1 with the values of the patient’s 
sensitivities to drugs as in Table 6-2 to show how we obtain the optimal 
values of the PID parameters. The full system is built by Simulink and 
optimised as shown in Figure 6.5. The PID initial parameters have been 
chosen as -1 for each parameter and written in an M-file. These values and 
the optimisation results are presented in Table 6-1. Figure 6.6 shows the 
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results of optimisation process for signal constraint of MAP and CO, the 
constraints which have been used in the simulation are between 478 and 
500 seconds for the settling time and 20% from the desired level of CO and 
MAP for overshoot. Figure 6.7 shows the optimal values of the controllers’ 
parameters which have been obtained 
 
Figure 6.5: Simulink Block Diagram of the System used for Optimisation with Result of case 1. 
 
Figure 6.6: The signal results of optimisation process. 
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Figure 6.7: The Output of of Optimisation Results. 
Table 6-1: The Initial and Optimisation Resultes of the Values of PID Controllers Parameters. 
Initial Values Optimisation Results 
Kp1 Ki1 Kd1 Kp2 Ki2 Kd2 Kp1 Ki1 Kd1 Kp2 Ki2 Kd2 
-1 -1 -1 -1 -1 -1 0.1822 0.0629 0.1415 -0.0098 0.054 1.0049 
 
The optimisation results achieved satisfactory performance and 
reached the desired level of MAP and CO. MAP decreases by 20 mmHg 
from the initial value and CO increases by 20 ml/min.kg from the initial value 
with optimal values of drug infusion rates. The parameters of PID were 
optimised offline to cover the wide range of patient’s sensitivities to drugs 
using Simulink Response. We have covered 12 patients’ cases based on the 
range values of the patient’s model parameters which are given in Table 5-1 
in chapter 5, section 5.2, and the details of these cases are presented in 
Table 6-2. The optimisation results are presented in Table 6-3. 
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Table 6-2: The Details of Patient’s Cases. 
Cases k11 𝛕11 T11 k12 𝛕12 T12 k21 𝛕21 T21 k22 𝛕22 T22 
1 1 70 15 -15 70 15 0 30 15 -13 30 15 
2 2 70 15 -7 70 15 1 30 15 -13.5 30 15 
3 3 70 15 2 70 15 1.5 30 15 -14 30 15 
4 4 70 15 8 70 15 2 30 15 -14.5 30 15 
5 5 300 60 12 150 50 3 40 60 -15 40 50 
6 6 300 60 12.2 150 50 4 40 60 -18 40 50 
7 7 300 60 12.4 150 50 5 40 60 -20 40 50 
8 8 300 60 12.6 150 50 5.5 40 60 -25 40 50 
9 9 600 60 12.7 600 60 6 60 60 -30 60 60 
10 10 600 60 12.8 600 60 7 60 60 -38 60 60 
11 11 600 60 12.9 600 60 8 60 60 -45 60 60 
12 12 600 60 13 600 60 9 60 60 -50 60 60 
 
Table 6-3: The Optimal Values of Controller’s Parameters. 
cases kp1 ki1 kd1 kp2 ki2 kd2 
1 0.1822 0.0629 0.1415 - 0.0098 0.054 1.0049 
2 0.2307 0.028 2.9405 - 0.0184 0.0595 0.5866 
3 0.0263 0.0403 0.2952 - 0.0099 0.0734 0.7434 
4 0.116 0.005 - 1.6066 - 0.0249 0.015 - 0.2066 
5 0.000623 0.12 0.1598 - 0.0124 0.03 0.3292 
6 0.004 0.025 - 0.3422 - 0.03 0.016 0.2911 
7 0.0311 0.0037 1.6602 0.0041 -0.055 - 2.4946 
8 0.0311 0.0048 1.6602 0.0041 -0.0495 2.4946 
9 0.2309 0.00102 0.6217 - 0.045 0.0046 0.8003 
10 0.235 0.00107 0.85 - 0.045 0.0029 0.8003 
11 0.235 0.001225 0.85 - 0.044 0.0045 3.65 
12 0.1999 0.0013 0.6119 - 0.0357 0.00381 0.6908 
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6.3 Neural Network Toolbox 
The neural network is widely used in fitting functions because of its 
ability to generalise, respond to unexpected inputs and to learn how to do 
tasks based on the data given for training. Neural Network Toolbox supports 
supervised and unsupervised network architectures. In this chapter the 
supervised networks have been used to retune the controller parameter. 
There are four types of supervised networks, feedforward, radial basis, 
dynamic and learning vector quantization. 
We have designed and utilised the neural network to make the 
controller able to work online and cover the wide range of patients. The 
supervised learning feedforward neural networks have been employed. The 
components of this neural network are four inputs and six outputs with three 
layers that input layer with four 4 neurons, hidden layer with twenty 20 
neurons and output layer with six 6 neurons. Figure 6.8 depicts the general 
structure of neural network. Figure 6.9 displays the structure of three layer 
feedforward neural network with one hidden layer. The first layer contains 
three input neurons, second is hidden layer with three neurons, and the third 
layer contains three output neurons. Appendix B Figure 7-1 to Appendix B 
Figure 7-5 shows the neural network model that has been obtained and 
implemented. The patient’s sensitivities to drugs DPM and SNP have been 
considered as inputs which are represented by K11, K12, K21, and K22. The 
PID parameters kp, ki and kd, have been considered as outputs to make the 
PID controller update. 
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Figure 6.8: Block Diagram of General Structure of Neural Network. 
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(Input Data)
Hidden Layer
(Process Data)
Output Layer
(Predicted Data)
 
Figure 6.9: Block Diagram of Structure of Three Layer Feedforward Neural Network. 
6.3.1 Procedure of training a neural network 
In order to make the PID controller update based on the patient’s 
condition, the neural network has been utilized. In the process of training a 
neural network, there are six steps to be made:  
1. Assemble and Normalize the data 
2. Create a Network project 
3. Creating a Training Set 
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4. Create a neural network 
5. Train the network 
6. Test the network to make sure that it is trained properly 
In neural network learning, data with different scales often lead to the 
instability of neural networks. The data that has been collected has different 
scales, due to that the data shown in Table 6-2 and Table 6-3 have been 
normalised and scaled between 0 and 1 using Equation (6.1). The data in 
Table 6-5 and Table 6-6 are inputs and outputs of neural network 
respectively. Table 6-4 lists minimum and maximum values of the 
parameters. 
Xi_new =
Xi − XMin
XMax − XMin
 (6.1) 
where, 
Xi_new  = the data point, normalised between (0-1).  
Xi  = each data point. 
XMin  = the minimum among all the data points. 
XMax  = the maximum among all the data points. 
 
In this part, we have took the data set of patient’s cases from the 
following Tables 6-2 and 6-3 to present the process of data normalisation, 
and the results are shown in Table 6-5, Table 6-6 and Table 6-7. From the 
data sets presented in Table 6-2 and Table 6-3 we have identified the 
Maximum and Minimum values of the patient’s sensitivities parameters and 
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the controller’s parameters as shown in Table 6-4. The neural network 
training procedure is presented in appendix A. 
Table 6-4: Maximum and Minimum Values of Inputs and Outputs Parameters. 
Patients’ sensitivities parameters 
K11_Max 12 K11_Min 1 
K12_Max 13 K12_Min - 15 
K21_Max 9 K21_Min 0 
K22_Max - 13 K22_Min - 50 
Controllers’ parameters 
Kp1_Max 0.235 Kp1_Min 0.000623 
Ki1_Max 0.12 Ki1_Min 0.00102 
Kd1_Max 2.9405 Kd1_Min - 1.6066 
Kp2_Max 0.0041 Kp2_Min - 0.045 
Ki2_Max 0.0734 Ki2_Min - 0.055 
Kd2_Max 3.65 Kd2_Min - 2.4946 
 
Table 6-5: Data Sets Normalisation Results of Patients’ Sensitivities “Inputs”. 
Cases k11_new k12_new k21_new k22_new 
1 0 0 0 1 
2 0.0909090909090909 0.285714285714286 0.111111111111111 0.986486486486487 
3 0.181818181818182 0.607142857142857 0.166666666666667 0.972972972972973 
4 0.272727272727273 0.821428571428571 0.222222222222222 0.959459459459459 
5 0.363636363636364 0.964285714285714 0.333333333333333 0.945945945945946 
6 0.454545454545455 0.971428571428571 0.444444444444444 0.864864864864865 
7 0.545454545454545 0.978571428571429 0.555555555555556 0.810810810810811 
8 0.636363636363636 0.985714285714286 0.611111111111111 0.675675675675676 
9 0.727272727272727 0.989285714285714 0.666666666666667 0.540540540540541 
10 0.818181818181818 0.992857142857143 0.777777777777778 0.324324324324324 
11 0.909090909090909 0.996428571428571 0.888888888888889 0.135135135135135 
12 1 1 1 0 
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Table 6-6: Data Sets Normalisation Results of 1
st
 Controller's Parameters “Outputs”. 
Cases kp1_new ki1_new kd1_new 
1 0.774721922372929 0.52008740964868 0.384442831694926 
2 0.98165348989022 0.226760800134476 1 
3 0.109554265136938 0.330139519246932 0.418244595456445 
4 0.492270999287473 0.0334510001680955 0 
5 0 1 0.388467374810319 
6 0.0144084103815647 0.201546478399731 0.278067339623056 
7 0.130034090375762 0.0225247940830392 0.718435926194717 
8 0.130034090375762 0.0317700453857791 0.718435926194717 
9 0.982506815941837 0 0.490048602405929 
10 1 0.000420238695579088 0.540256427173363 
11 1 0.00172297865187426 0.540256427173363 
12 0.850241277941095 0.0023533366952429 0.4878933825955 
 
Table 6-7: Data Sets Normalisation Results of 2
nd
 Controller’s Parameters “Outputs”. 
Cases Kp2_new Ki2_new Kd2_new 
1 0.716904276985743 0.848909657320872 0.569524460501904 
2 0.541751527494908 0.891744548286604 0.501448426260456 
3 0.714867617107943 1 0.526966767568271 
4 0.409368635437882 0.545171339563863 0.372359470103831 
5 0.663951120162933 0.661993769470405 0.459557985873775 
6 0.305498981670061 0.552959501557632 0.453357419522833 
7 1 0 0 
8 1 0.0428348909657321 0 
9 0 0.46417445482866 0.536226930963773 
10 0 0.450934579439252 0.536226930963773 
11 0.0203665987780041 0.463395638629283 1 
12 0.189409368635438 0.458021806853583 0.518406405624451 
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6.4 Experimental Results 
Matlab Simulink has been used to simulate the patients’ model 
presented in Figure 6.2 and the PID controllers’ parameters named kp1, ki1, 
kd1, kp2, ki2 and kd2 have been tuned using neural networks. Table 5-1 in 
chapter 5 presents the ranges of values of the patient’s sensitivity. The 
patient’s sensitivity to drug varies from patient to patient. Due to this, the 
drug infusion controller should be designed to work well in a real-time 
environment for a wide range of patients. In the simulation, the automatic 
multiple drug delivery system simulates MAP and CO using DPM and SNP 
with different sensitivity. The PID controller based on neural network has 
been implemented to control the infusion rate of the drugs. The controller has 
been adapted using the neural network with patients’ sensitivities as inputs 
and controllers’ parameters as the outputs to make the controller suitable for 
a wide range of patients. The system has been tested using different 
patient’s sensitivity, and the parameters’ values of the patient’s model have 
included different types of patient’s sensitivities to drugs. The patients’ 
sensitivities to DPM have been represented by K11 and K12. K21 and K22 have 
represented the patients’ sensitivities to SNP. 
Data in Table 6-3 represent the optimal values of the PID controllers’ 
parameters which have been obtained by the implementation of SDOT. 
These results have been relied upon to employ the neural network to control 
the multi-drug infusion control system and cover the wide range of patients 
with and without disturbances. From these results we observe that the 
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proposed algorithm is able to control simultaneously MAP and CO using two 
drugs. The results demonstrate the controller is able to cover the wide range 
of patients. 
Table 6-8: Patient Response to DPM and SNP without the Impact of Disturbances. 
Cases 
Patients' sensitivities 
DPM 
“µg/min.kg” 
SNP 
“µg/min.kg” 
CO 
“ml/min.kg” 
MAP 
“mmHg” 
K11 K12 K21 K22 
1 1 -15 0 -13 43.08 1.54 20 -20 
2 2 -7 1 -13.5 20.50 3.00 20 -20 
3 3 2 1.5 -14 5.33 2.00 20 -20 
4 4 8 2 -14.5 1.76 1.62 20 -20 
5 5 12 3 -15 0.54 1.44 20 -20 
6 6 12.2 4 -18 0.74 1.28 20 -20 
7 7 12.4 5 -20 0.75 1.19 20 -20 
8 8 12.6 5.5 -25 0.92 1.00 20 -20 
9 9 12.7 6 -30 1.00 0.87 20 -20 
10 10 12.8 7 -38 1.07 0.72 20 -20 
11 11 12.9 8 -45 1.07 0.64 20 -20 
12 12 13 9 -50 1.03 0.59 20 -20 
 
 
 
 
 
 
 
CHAPTER 6. – ADAPTIVE MULTI-DRUG NEURO-PID CONTROL SCHEME FOR BLOOD PRESSURE 
CONTROL 
 
134 
 
 
Table 6-9: Patient Response to DPM and SNP with the Impact of Disturbances, D1 and D2 = 0.05. 
Cases 
Patients' sensitivities 
DPM 
“µg/min.kg” 
SNP 
“µg/min.kg” 
CO 
“ml/min.kg” 
MAP 
“mmHg” 
K11 K12 K21 K22 
1 1 -15 0 -13 43.07 1.54 19.96 -20.05 
2 2 -7 1 -13.5 20.51 3.00 19.95 -20.06 
3 3 2 1.5 -14 5.33 2.00 19.94 -20.05 
4 4 8 2 -14.5 1.76 1.62 19.94 -20.07 
5 5 12 3 -15 0.54 1.44 19.95 -20.05 
6 6 12.2 4 -18 0.74 1.27 19.94 -20.03 
7 7 12.4 5 -20 0.75 1.19 19.94 -20.05 
8 8 12.6 5.5 -25 0.92 1.00 19.94 -20.05 
9 9 12.7 6 -30 1.01 0.87 19.95 -19.95 
10 10 12.8 7 -38 1.09 0.73 19.95 -19.94 
11 11 12.9 8 -45 1.09 0.64 19.95 -19.94 
12 12 13 9 -50 1.04 0.59 19.95 -19.92 
From these results we have selected some cases from Table 6-8 and 
Table 6-9 above. These cases are 1, 6, and 12 to show the patients’ 
responses to drug with and without disturbances. The results of simulation 
demonstrate that the PID controller based on neural network is able to cover 
different types of patients in real-time with acceptable results. 
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Table 6-10: Performances of Neuro-PID Adaptive Control for MAP and CO Regulation. 
Cases 
Settling Time Overshoot 
MAP (mmHg) CO (ml/min.kg) MAP (mmHg) CO (ml/min.kg) 
1 475 378 zero 0.31 
2 416 427 zero zero 
3 559 810 zero zero 
4 819 643 zero Zero 
5 597 1183 zero zero 
6 541 1514 zero zero 
7 856 663 1.15 0.08 
8 801 650 1.61 0.18 
9 450 588 0.38 0.04 
10 1103 649 zero zero 
11 1003 486 1.21 0.01 
12 661 553 0.51 0.07 
Figure 6.10, Figure 6.11 and Figure 6.12, show the simulation 
results of the patient responses to drug infusion rates. They also, illustrate 
the response of the patient to DPM and SNP when increase CO of 20 
ml/min.kg and decrease MAP of 20 mmHg from the initial values. The results 
in Table 6-10 clearly demonstrate the controller performance is better with 
less settling time and overshoot compared to the performance of the non-
adaptive PID controller in chapter four and with the performance of MRAC in 
chapter five. In addition this algorithm is able to simulate online MAP and CO 
by obtaining the optimal infusion rates of the drugs and cover a wide range of 
patients’ cases. 
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Figure 6.10: CASE (1) Patient Response (CO and MAP) to drugs (DPM and SNP) with and 
without the Impact of Disturbances. 
 
Figure 6.11: CASE (6) Patient Response (CO and MAP) to drugs (DPM and SNP) with and 
without the Impact of Disturbances. 
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Figure 6.12: CASE (12) Patient Response (CO and MAP) to drugs (DPM and SNP) with and 
without the Impact of Disturbances. 
6.5 Summary 
Control of physiological states such as mean arterial pressure (MAP) 
has been successfully achieved using single drug by different control 
algorithms. Multi-drug delivery demonstrates a significantly challenging task 
as compared to control with a single-drug. Also the patient’s sensitivity to the 
drug varies from patient to patient. Therefore, the implementation of adaptive 
controller is very essential to improving dealing with the variety of patient 
physiological responses. This chapter presents the design and 
implementation of a PID based on neural network. The function of this 
scheme is to update the PID controller to regulate MAP and CO of the 
different patients by administering vasoactive and inotropic drugs SNP and 
 
CHAPTER 6. – ADAPTIVE MULTI-DRUG NEURO-PID CONTROL SCHEME FOR BLOOD PRESSURE 
CONTROL 
 
138 
 
 
DPM respectively. The parameters of the PID controller were optimised 
offline using Simulink Response Tool.  
This chapter has presented an adaptive multi-drug Neuro-PID control 
scheme for blood pressure control. The proposed scheme was designed and 
evaluated in simulation study to maintain the nonlinear responses of CO and 
MAP using two drugs, namely DPM and SNP for the patients of various 
sensitivities. The simulation results have confirmed that the PID based on 
neural network is potentially useful for regulating the MAP and CO. The 
proposed approach offers much better performance compared to existing 
approaches to cover a wide range of patients. 
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Chapter 7.  
CONCLUSIONS AND FUTURE WORK 
7.1 Conclusion 
The main focus of this thesis was divided in two parts; the first part 
was to compare the performance of two control strategies which have been 
considered to achieve the optimal infusion rate of a single drug SNP in order 
to regulate MAP. The PID and IMC controllers have been implemented to 
control blood pressure using three types of patient’s sensitivities to SNP. The 
GAs optimization methods have been implemented to find the optimal values 
of controllers’ parameters. The simulation results have demonstrated the PID 
controller achieved much smaller settling times than the IMC which has been 
demonstrated in [47, 49]. The sensitive patient response has a little 
overshoot but this is much less than the performance criteria set in [42]. 
In the second part of the research work an adaptive multi-drug control 
scheme was developed and implemented to regulate the patients’ MAP and 
CO by infusing the optimal infusion rates of two drugs SNP and DPM. The 
MRAC was designed and evaluated by simulating variations in patient 
sensitivity to drugs and with disturbances in MAP and CO. The simulation 
results have confirmed MRAC is potentially useful for regulating MAP and 
CO by computing the DPM and SNP infusion rates. The proposed algorithm 
demonstrated better performance compared to the non-adaptive PID 
 
CHAPTER 7. – CONCLUSIONS AND FUTURE WORK  
 
140 
 
 
controller. In the simulation studies, the proposed scheme produced better 
performance compared to existing researchers’ results, particularly for the 
updated controller’s gain. This includes shorter settling time and very small 
or no overshoot when the patient sensitivity K22 is less than or equal 20. 
In chapter six an adaptive multi-drug Neuro-PID control scheme for 
blood pressure control was developed and implemented. The proposed 
scheme was designed to overcome the problem of having a linear patient 
model which does reflect the range of dynamics of patients in real-life. The 
main benefit of the Neuro-PID is its ability to capture the nonlinear responses 
of MAP and CO to the drugs, DPM and SNP and cope with various patients 
sensitivities. The simulation results have confirmed that PID controller based 
on neural network has a good performance and can cope with a wide range 
of patient. 
7.2 Limitations of Study 
This study focused on the control of mean arterial pressure and 
cardiac output. Other hemodynamic variables could be incorporated in the 
control system. 
In this study the patient’s model that was used was a SISO and MIMO 
input-output transfer function with time delays. This model does not entirely 
capture the real-life patient reactions to drugs. In view of this, the neural 
network system in chapter 6 was developed to capture the variations  
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7.3 Future Work 
The simulation results in this thesis have achieved the main 
objectives, and the algorithms have provided good performance. However, 
future work may include the following: 
 The logical step is to apply and test the SISO and MIMO control systems 
presented in chapters 4 and 6 in clinical trials using animals. 
 Implement interactive MIMO control instead of using two SISO control 
loops. 
 Extend the patients’ model to manage more primary physiological 
parameters of the hemodynamic variables for instance mean pulmonary 
arterial pressure (MPAP) as the output with more intravenous infusion 
drug such as phenylephrine (PNP) as input.  
 In this research a first order patient’s model with time delays was used in 
the simulations. A better model is obtained by getting real data from 
patients and using a neural network to obtain a nonlinear model which 
would describe better the patients’ response to various drugs. 
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APPENDIXES 
APPENDIX A: NEURAL NETWORK TRAINING PROCEDURE 
Step 1:  The neural network fitting tool with a two-layer feed-forward 
network, sigmoid hidden neurons and output neurons. The input is 
a data set of patent’s sensitivities to drugs and output is a data set 
of controller’s parameters, as shown in Appendix A Figure 7-1.  
Step 2:  Select data of the input and output and inserted as matrix, the 
inputs data as IN and the outputs data as OUT. Appendix A 
Figure 7-2 illustrates this step.  
Step 3:  Select the percentages for validation and testing data, the rest of 
percentages will be for training as shown in Appendix A Figure 
7-3. 
Step 4:  Network size, selecting the numbers of hidden neurons, these 
numbers have been selected as 20 hidden layers, Appendix A 
Figure 7-4 shows that. 
Step 5:  Train network, the network start training to fit the inputs and 
outputs, and training progress which present the training results 
as shown in Appendix A Figure 7-5. 
Step 6:  Present training result by plot and present the best validation 
performance result as shown in Appendix A Figure 7-6. 
Step 7:  Present training result by plot training state as in Appendix A 
Figure 7-7.   
Step 8:  Present training result by plot of training, validation and test 
results, the regression (R) values have reach the optimal value as 
shown in Appendix A Figure 7-8. 
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Step 9:  Present training result by plot of regression, the result of this step 
has reach the optimal value of regression, as shown in Appendix 
A Figure 7-9. 
Step 10:  Save network training results as simulink file, the neural network 
simulink model has shown in Appendix A Figure 7-10 and 
employed in the system. 
 
Appendix A Figure 7-1: The Neural Network Fitting Tool. 
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Appendix A Figure 7-2: Select Input Data as IN and Outputs Data as OUT. 
 
Appendix A Figure 7-3: The Percentages of Validation and Test Data. 
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Appendix A Figure 7-4: Network Size, 20 Hidden Layers. 
 
Appendix A Figure 7-5: Training Results. 
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Appendix A Figure 7-6: The Best Validation Performance Result. 
 
Appendix A Figure 7-7: Training States. 
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Appendix A Figure 7-8: Training, Validation and Test Result. 
 
Appendix A Figure 7-9: Training Regression Result. 
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Appendix A Figure 7-10: Neural Network Simulink Model. 
APPENDIX B: NEURAL NETWORK MODEL 
 
Appendix B Figure 7-1: Simulink Block Diagram of Neural Network Model. 
 
 
Appendix B Figure 7-2: Simulink Block Diagram of Hidden Layer (Layer 1). 
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Appendix B Figure 7-3: Simulink Block Diagram of Hidden Layer with 20 Neurons. 
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Appendix B Figure 7-4: Simulink Block Diagram of Output Layer (Layer 2). 
 
 
Appendix B Figure 7-5: Simulink Block Diagram of Output Layer with 6 Neurons. 
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